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1. Introduction 
Hypopharyngeal cancers arise from the mucosa of one of the three anatomical subsites of 
the hypopharynx and are characterised by advanced disease at presentation mainly because 
the hypopharynx, laying outside the glottis and being a silent area, allows tumours to grow 
for a substantial period of time before symptoms occur (Elias et al., 1995; Sewnaik et al., 
2005). Hypopharyngeal cancers are relatively rare neoplasms and have one of the most 
unfavourable prognosis among all cancers of the upper aerodigestive tract (Prades et al., 
2002; Samant et al., 1999). The reasons for the remarkably poor prognosis of hypopharyngeal 
cancers is their aggressive behaviour represented by strong tendency for submucosal 
spread, early occurrence of nodal metastatic involvement, propensity for direct invasion of 
adjacent structures in the neck and high incidence of distant metastases (Elias et al., 1995; 
Johansen et al., 2000).  
Treatment options for early stage hypopharyngeal cancer include conservation or radical 
surgery or radiotherapy, whereas total laryngectomy with partial or total pharyngectomy 
followed by postoperative radiotherapy have been the standard form of treatment for 
advanced stage disease. Over the past two decades, organ preservation strategies with either 
altered fractionation radiotherapy or combination of chemotherapy and radiotherapy have 
been used for the treatment of advanced hypopharyngeal cancers. Progressive tumour-
related dysphagia prior to diagnosis, associated tobacco and alcohol use, commonly older 
age, medical comorbidities and social issues present in most of the patients, unequivocally 
contribute to additional challenges for employment of aggressive treatment management, 
and increase the risk of morbidity and mortality following therapy. The complex 
management of these tumours creates an essential need for multidisciplinary team approach 
involving a head and neck surgeon, radiation oncologist, medical oncologist, radiologist, 
pathologist, nutritionist, speech and swallow therapist, and social worker. This chapter will 
review the epidemiology and etiology, clinical presentation, diagnosis, prognosis, treatment 
modalities for early and locally-regionally advanced resectable hypopharyngeal cancer, 
management of unresectable disease, and treatment of recurrent and metastatic disease. 
2. Epidemiology and etiology 
Hypopharyngeal cancer is a rare disease representing about 0.5% of all human malignancies 
with an incidence of less than 1 per 100,000 population and constituting only 3%–5% of all 
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head and neck cancers (Cooper et al., 2009; Hoffman et al., 1998; Johansen et al., 2000). 
Hypopharyngeal cancers are more common in men than in women. Increased incidence in 
males of over 2.5:100,000 is seen in India, Brazil, Central and Western Europe and decreased 
incidence under 0.5:100,000 in Eastern Asia, Africa and Northern Europe. The incidence in 
women is as high as 0.2:100,000 in the majority of the countries, except for India (1:100,000) 
(Popescu et al., 2010). These tumours typically occur in individuals who are older than 50 
years of age, with a peak incidence in the sixth and seventh decades and their occurrence is 
extremely rare in children (Siddiqui et al., 2003). The most common site of origin of 
hypopharyngeal cancer is the pyriform sinus (66%–75%), followed by the posterior 
pharyngeal wall, and postcricoid area (20%–25%) (Carpenter & DeSanto, 1977). There are 
differences in the geographical distribution of the hypopharyngeal cancer with regard to 
tumour location and patient gender, with postcricoid lesions showing a consistent moderate 
female preponderance  particularly in Scandinavia (Farrington et al., 1986; Kajanti & 
Mantyla, 1990; Lederman, 1962;  Popescu et al., 2010; Tandon et al., 1991). Pyriform sinus 
and posterior pharyngeal wall lesions demonstrate typical male predominance in North 
America and especially in France (Vandenbrouck et al., 1987).  
Excessive tobacco and alcohol consumption contribute to the development of squamous cell 
carcinomas in the upper aerodigestive tract (Flanders & Rothman, 1982; Jayant et al., 1977). 
Тobacco and alcohol represent the major risk factors for the development of 
hypopharyngeal cancer with more than 90% of patients presenting with a history of tobacco 
use (Hoffman et al., 1997). Risk increases with both the quantity and duration of tobacco and 
alcohol use (Menvielle et al., 2004; Tuyns et al., 1988). An increased smoking rate in women 
resulted in narrowing the gap between genders in some countries (Llatas et al., 2009; 
Popescu et al., 2010). Also, the early introduction of smoking in the individual habits could 
be considered as a factor contributing to a downward readjustment of the age of appearance 
of hypopharyngeal cancer (Lefebvre & Chevalier, 2004). The high rate of synchronous and 
metachronous primary tumours identified in patients with hypopharyngeal cancer and the 
concomitant mucosal dysplasia frequently found surrounding primary tumours appear to 
relate to a field cancerisation effect, which is consistent with widespread exposure to 
carcinogens (Shah et al., 2008; Slaughter et al., 1953; Van Oijen & Slootweg, 2000).  
The importance of the role of genetic factors for the development of head and neck cancer is 
not fully understood at the present time. Abnormalities of the tumour suppressor gene p53 
are common in hypopharyngeal cancer, occurring in up to 70% of patients (Somers et al., 
1992). The association between tobacco use and p53 mutations is found in a much larger 
percentage of smokers and drinkers than that of nonsmokers and nondrinkers (Brennan et 
al., 1995; Koch et al., 1999; Sorensen et al., 1997). Also, the overexpression of oncogenes at 
the 11q13 locus appears to be more frequent in hypopharyngeal cancers compared with 
other head and neck cancer (Muller et al., 1997; Williams et al., 1993). The loss of 
heterozygosity at 9p and abnormalities in chromosome 11 present in histologically normal 
mucosa adjacent to hypopharyngeal cancers further support the field cancerisation effect 
hypothesis (Van der Riet et al., 1994). Mutations in the p21 gene have also been identified in 
hypopharyngeal cancers (Ernoux-Neufcoeur et al., 2011). 
The role of human papilloma virus (HPV) as a contributing factor to carcinogenesis in head 
and neck squamous cell carcinomas represent an area of active investigation (Fakhry & 
Gillison, 2006). Although the association of HPV with head and neck cancer, especially with 
www.intechopen.com
 Hypopharyngeal Cancer 
 
15 
oropharyngeal tumours has been supported by epidemiologic and molecular biology 
studies (Franceschi et al., 1996; McKaig et al., 1998), HPV in the carcinogenesis of 
hypopharyngeal cancer is less well defined. Studies have demonstrated rates of detection of 
HPV DNA in patients with hypopharyngeal cancer ranging from 20% to 25% (Mineta et al., 
1998). However, the clinical implications of the presence of the genome of the oncogenic 
high-risk HPV types in hypopharyngeal cancer are yet to be defined. 
The development of hypopharyngeal cancers in the postcricoid area in women aged 30 to 50 
without a history of tobacco or alcohol use is associated with previous Plummer-Vinson 
syndrome, also termed Patterson-Brown-Kelly syndrome (Goldstein et al., 2008; Kajanti & 
Mantyla, 1990; Stell et al., 1978). This syndrome is characterised by hypopharyngeal webs, 
dysphagia, weight loss, and iron-deficiency anemia. Its early diagnosis and treatment with 
supplemental iron were shown to be effective in stooping further cancer development 
(Pfister et al., 2009).  
A substantial proportion of hypopharyngeal cancers could be attributable to occupational 
exposures (Menvielle et al., 2004). Possible environmental carcinogens that have been 
implicated in hypopharyngeal cancer include asbestos and welding fumes (Gustavsson et 
al., 1998; Marchand et al., 2000; Shangina et al., 2006).  
3. Anatomy of the hypopharynx 
The hypopharynx is the part of the pharynx that is contagious superiorly with the 
oropharynx and is situated posterior and lateral to the larynx. The hypopharynx extends 
from the superior border of the epiglottis and the pharyngoepiglottic folds from the level of 
the hyoid bone superiorly to the lower border of the cricoid cartilage inferiorly where it 
narrows and becomes continuous with the esophagus (Gale et al., 2006; Moore et al., 2010). 
It is divided into three primary anatomic subsites: the pyriform sinuses, the postcricoid area, 
and the posterior pharyngeal wall. 
The pyriform sunuses are analogous to an inverted pyramids situated lateral to the larynx 
with their base located superiorly and with the anterior, lateral, and medial walls narrowing 
inferiorly to form the apices with their tips extending slightly below the cricoid cartilage. It 
is separated from the laryngeal inlet by the aryepiglottic fold. The superior limit of the base 
is the pharyngoepiglottic fold and the free margin of the aryepiglottic fold. The lateral wall 
of the pyriform sinus is formed by the inferior constrictor muscles and the internal branches 
of the superior laryngeal neurovascular bundle. Its superior aspect is bordered by the 
thyrohyoid membrane. Inferiorly, it is bounded by the thyroid cartilage. Its medial 
boundary is the lateral surface of the aryepiglottic fold, arytenoids, and lateral aspect of the 
cricoid cartilage. The median wall is formed by the lateral surface of the aryepiglottic fold, 
arytenoids, and lateral aspect of the cricoid cartilage (Moore et al., 2010).  
The postcricoid area includes the mucosa that overlies the cricoid cartilage and represents 
the anterior surface extending from the superior aspect of the arytenoid cartilages to the 
inferior border of the cricoid cartilage. Inferiorly, it is contagious with the cervical 
esophagus. Its important relations are the arytenoids, the cricoarytenoid joints, the intrinsic 
laryngeal muscles, and inferiorly, below the cricoid, the trachealis muscle and recurrent 
laryngeal nerves.  
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Posterior pharyngeal wall extends superiorly from the horizontal level of the floor of the 
vallecula (the level of the hyoid bone) to the inferior border of the cricoid inferiorly and 
laterally from the apex of one pyriform sinus to the other being contagious with the lateral 
wall of the pyriform sinus. The posterior pharyngeal wall is predominantly comprised of 
mucosa covering the middle and inferior pharyngeal constrictor muscles. Posteriorly, it is 
related to the bodies of the third through sixth cervical vertebra. It is separated from the 
prevertebral fascia by retropharyngeal space. The posterior pharyngeal wall is contagious 
with the lateral wall of the pyriform sinus. 
There is a rich network of lymphatic channels within the hypopharynx. The first echelon of 
lymphatic drainage is represented by the upper and midjugular (level II and III) nodes. 
Lymphatic channels from the pyriform sinuses drain through the thyrohyoid membrane 
following the superior laryngeal artery to the jugulodigastric, midjugular (level II and III), 
and retropharyngeal nodes. The lymphatics of the postcricoid area may drain directly to 
local lymph nodes, may ascend with the lymphatic drainage of the pyriform sinus (levels II 
and III), but mainly tend to follow the retropharyngeal lymph nodes to the paratracheal, 
paraesophageal, and lower jugular nodes (level IV and VI), or may occasionally drain down 
into the superior mediastinum (Clayman & Weber, 1996). Lymphatics of the posterior 
pharyngeal wall may drain bilaterally, passing to the lateral retropharyngeal nodes 
including the most cephalad retropharyngeal nodes of Rouviere, or to the upper jugular 
nodes (level II).  
The sensory innervation of the hypopharynx is by the glossopharyngeal and vagus nerves 
via the pharyngeal plexus, superior laryngeal nerves, and recurrent laryngeal nerves (Moore 
et al., 2010). The common origin of the auricular nerve of Arnold from the synapsis of the 
internal branch of the superior laryngeal nerve and the vagal branches from the middle ear 
in the jugular ganglion results in the phenomenon of referred otalgia seen in patients 
presenting with hypopharyngeal cancer (Clayman & Weber, 1996). Motor innervation of the 
hypopharynx is from the pharyngeal plexus and recurrent laryngeal nerves. The arterial 
supply is derived from the superior laryngeal, lingual, and ascending pharyngeal collateral 
arteries (Standring, 2004).  
4. Patterns of spread and clinical presentation 
4.1 Patterns of spread 
Hypopharyngeal cancers, particularly those arising in the postcricoid area, have a strong 
tendency for extensive submucosal spread. The extent of subclinical spread beyond the 
macroscopic tumour edge is greatest in the inferior direction ranging between 5 and 30 mm 
(Davidge-Pitts & Mannel, 1983; Hong et al., 2005). The presence of submucosal tumour 
extension frequently demonstrated in surgical specimens can result in inaccuracy in the 
estimation of tumour volume. Therefore, the submucosal spread as a characteristic feature 
for hypopharyngeal cancer should be taken into consideration during the treatment being 
either surgery or radiotherapy. Pyriform sinus cancers with lateral extension can invade the 
thyroid cartilage (Kirchner, 1975), but cricoid cartilage and thyroid gland involvement is 
also possible by the extension through the cricothyroid membrane. Medial extension is 
associated with invasion of the aryepiglottic folds, preepiglottic and paraglottic space, and 
intrinsic laryngeal muscles that results in a loss of vocal cord mobility (Kirchner, 1975; Tani 
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& Amatsu, 1987). Superior tumour extension beyond the lateral pharyngoepiglottic fold into 
the vallecula can involve the base of the tongue and inferior tumour extension beyond the 
apex can involve the thyroid gland. Postcricoid tumours tending to grow circumferentially 
frequently involve the cricoid cartilage, arytenoids and intrinsic laryngeal muscles with 
resultant vocal cord fixation. Involvement of the recurrent laryngeal nerve can also result in 
vocal cord immobility. The inferior tumour spread can lead to invasion of cervical 
esophagus and trachea. Posterior pharyngeal wall tumours with their superior spread may 
invade the base of the tonsil and the oropharyngeal wall, while inferior extension may be 
associated with invasion of the postcricoid hypopharynx. These tumours may also invade 
through the posterior wall to involve the prevertebral fascia and the vertebral bodies. 
Lymph node metastases in the neck are associated with even the earliest stages of 
hypopharyngeal cancer.  Metastases in the neck lymph nodes are already present in 
approximately 70% of patients at the time of presentation with levels II and III being the 
most frequently affected sites (Lefebvre et al., 1987; Vandenbrouck et al., 1987). Metastases 
in paratracheal and paraesophageal nodes (level VI) are most commonly present in patients 
with cancers in the postcricoid area (De Bree et al., 2011; Joo et al., 2010; Timon et al., 2003; 
Weber et al., 1993). Retropharyngeal lymph node metastases are most frequently present in 
patients with cancers of the posterior pharyngeal wall and the postcricoid area, but can also 
be present in those patients who have positive nodes in other levels in the neck (Amatsu et 
al., 2001; Hasegawa & Matsuura, 1994; Kamiyama et al., 2009). Apart from the high 
incidence of clinically apparent regional spread, another striking problem is the presence of 
occult nodal disease in high percentage of patients with hypopharyngeal primaries. Thus, in 
patients with clinically positive neck, the incidence of bilateral occult lymph node 
metastases is at least 50% (Byers et al., 1988; Buckley & MacLennan, 2000). The reported 
percentage of occult contralateral neck metastases in patients with pyriform sinus cancer 
and ipsilateral metastatic neck nodes involvement is 77% (Aluffi et al., 2006). Bilateral occult 
lymph node metastases in patients with clinically negative neck are most frequently 
associated with cancers of the pyriform sinus (Buckley & MacLennan, 2000; Koo et al., 2006). 
The risk of occult lymph node metastases at levels IV and V in patients with clinically 
negative neck is low, whereas in patients with clinically positive neck is more than 20% 
(Byers et al., 1988; Buckley & MacLennan, 2000; Gregoire et al., 2000). Occult nodal disease 
in ipsilateral paratracheal lymph nodes has been reported in 20% of patients with tumours 
arising from postcricoid area or pyriform sinus apex presenting with clinically negative neck 
(Buckley & MacLennan, 2000). 
Distant metastases at presentation are more common in hypopharyngeal cancers than in 
other head and neck cancers. At the time of clinical diagnosis distant metastatic disease is 
present in approximately 17% of hypopharyngeal cancers (Hsu & Chen, 2005; Spector, 2001). 
The frequency of distant metastatic development in patients with hypopharyngeal cancer 
during the course of the disease is also among the highest of all head and neck cancers. In 
the ten years experience of treatment for advanced hypopharyngeal cancer reported by 
Hirano et al. (Hirano et al., 2010), approximately half of the recurrences was distant 
metastatic disease. The most common site for distant metastases is the lung. According to 
Spector et al. (Spector et al., 2001), development of distant metastases at some time  
following initial treatment is associated with tumour recurrence at the primary site, or  
neck metastases. 
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4.2 Clinical presentation 
Early hypopharyngeal cancers produce a mild, nonspecific sore throat or vague discomfort 
on swallowing. In these patients, globus sensation can be the only complaint with normal 
clinical findings (Tsikoudas et al., 2007). However, the majority of patients with cancers of 
the hypopharynx presents with advanced local and/or regional disease and provide a 
history of significant tobacco or alcohol use. Most patients have also poor dentition and 
halitosis. Predominating symptoms are those related to the locoregional disease spread 
including sore throat, odynophagia and dysphagia, weight loss, and a mass in the neck. 
Referred otalgia (external auditory canal pain) frequently present in patients with pyriform 
sinus cancers may be referred via the superior laryngeal nerve through the auricular branch 
of the vagal nerve (Arnold’s nerve). Development of hoarseness (vocal cord paralysis) may 
be a result of either direct invasion of the larynx or involvement of recurrent laryngeal nerve 
indicating more advanced disease. A “hot potato” voice may be due to the involvement of 
the base of the tongue. Approximately 50% of patients present with palpable neck 
lymphadenopathy as the only complaint on initial clinical examination (Keane, 1982; 
Uzcudun et al., 2001).  
5. Diagnosis, staging, and prognosis 
5.1 Diagnosis 
Pretreatment diagnostic workup of hypopharyngeal cancer starts with a complete medical 
history with attention paid to disease-related signs and symptoms, and continues with 
clinical examination and endoscopy including indirect mirror exam and fiberoptic 
endoscopy under local anesthesia. Clinical and endoscopic assessment should be focused on 
determining the extent of the primary tumour and laryngeal mobility. Endoscopy can often 
easily reveal tumours arising in the upper pyriform sinus and the posterior pharyngeal wall, 
whereas for tumours located in the apex of the pyriform sinus and obscured by pooled 
secretions, and for those arising in postcricoid area and causing significant arytenoid edema, 
the visualisation of the tumour during endoscopy is much more difficult. Panendoscopy 
under general anesthesia allows the physician a thorough evaluation of the entire upper 
aerodigestive tract with consequent precise assessment of the macroscopic extent of the 
primary tumour as well as detection of synchronous primary tumours. Detection of regional 
disease is obtained by careful examination of both sites of the neck. 
Imaging studies including computed tomography (CT) and/or magnetic resonance imaging 
(MRI) and/or positron emission tomography (PET)/CT of the head and neck region are 
required to define the extent of the disease at the primary site in surrounding structures, 
such as the paralaryngeal space, preepiglottic space, laryngeal cartilages, extralaryngeal soft 
tissue, prevertebral space, and parapharyngeal space, and also to evaluate the extent of the 
disease in regional lymph nodes. Imaging studies are primarily helpful for staging the 
primary tumour and neck, but may also help in determining mediastinal spread and distant 
metastatic disease in the lung and can also inform on possible synchronous tumours in the 
upper aerodigestive tract. Fluorodeoxyglucose-PET (FDG-PET) scans, although not 
routinely indicated, may be helpful in the evaluation of locally advanced hypopharyngeal 
cancer. Histological confirmation is mandatory for the diagnosis of hypopharyngeal cancer. 
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Biopsy of primary tumour site is usually performed during endoscopic examination under 
anesthesia. If a neck adenopathy is present, ultrasound with a fine-needle aspiration or core 
biopsy is performed obtaining sufficient tumour to confirm diagnosis of suspicious 
metastatic lymph node. More than 95% of hypopharyngeal malignancies are squamous cell 
carcinomas which are often poorly differentiated. Uncommon nonsquamous cell 
malignancies include adenocarcinoma, composing the majority of the remaining 5% of the 
primary hypopharyngeal tumours, as well as lymphoma, and other rare neoplasms such as 
malignant fibrous histiocytoma, liposarcoma, fibrosarcoma, chondrosarcoma, and mucosal 
malignant melanoma. 
Pretreatment evaluations should also include routine laboratory studies (a complete blood 
count, basic blood chemistry, liver function tests, and renal function tests), chest x-ray, and 
liver ultrasound. Swallowing and nutrition status should be also evaluated. When 
radiotherapy planned, preventive dental care and dental extractions should be dealt with 10 
to 14 days prior to treatment commencement. 
5.2 Staging 
The accepted standard for staging of hypopharyngeal squamous cell carcinoma is 
represented by the American Joint Committee on Cancer (AJCC) Tumour Node Metastasis 
(TNM) staging system (Edge & Byrd, 2009) (Table 1). Clinical staging is based on data from 
medical history, clinical examination, endoscopy, and imaging studies. Regarding the 
primary tumour, the AJCC staging system does not differentiate the specific tumour subsite. 
Regional lymph nodes staging and stage grouping is identical to other sites within the oral 
cavity and pharynx with exception of nasopharynx. Pathologic staging is based on findings 
from clinical staging and data included in the report of histopathological analysis for 
resected specimen including the type, size, and grade of the primary tumour, the pattern of 
invasion, the minimum resection margin, the regional lymph nodes status, and the presence 
of nodal extracapsular extension. 
5.3 Prognostic factors 
Overall stage grouping (anatomic stage), stage of primary tumour (T stage), and stage of 
regional lymph nodes (N stage) are important prognostic factors for cancer of the 
hypopharynx. Regarding the data from literature concerning prognostic factors for 
hypopharyngeal cancer, it is apparent that the results of the analysis of different authors are 
not consistent. Thus, some authors showed nodal staging as the most important 
independent prognostic factor (Keane et al., 1983; Pivot et al., 2005; Sakata et al., 1998), 
whereas other authors confirmed the statistical significance of T stage (Toita et al., 1996; 
Tsou et al., 2006). According to some authors, overall stage grouping remains the most 
important determinants of outcome (Barzan et al., 1990; Gupta et al., 2009a), while other 
authors revealed T stage and N stage as dominant prognostic factors in hypopharyngeal 
cancer (Hall et al., 2009; Johansen et al., 2000; Spector et al., 1995; Wygoda et al., 2000).  
Age and gender have been also shown to have prognostic significance in hypopharyngeal 
cancer with increased age and male gender negatively influencing patients’ outcome 
(Nishimaki et al., 2002; Rapoport & Franco, 1993; Spector et al., 1995).  
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Primary tumour (T) 
TX: Primary tumour cannot be assessed 
T0: No evidence of primary tumour 
Tis: Carcinoma in situ 
T1: Tumour limited to one subsite of hypopharynx and/or 2 cm or less in greatest 
dimension 
T2: Tumour invades more than one subsite of hypopharynx or an adjacent site, or 
measures more than 2 cm, but not more than 
4 cm in greatest dimension without fixation of hemilarynx 
T3: Tumour more than 4 cm in greatest dimension or with fixation of hemilarynx or 
extension to esophagus 
T4a: Moderately advanced local disease. Tumour invades thyroid/cricoid cartilage, 
hyoid bone, thyroid gland, or central compartment soft tissue* 
T4b: Very advanced local disease. Tumour invades prevertebral fascia, encases carotid 
artery, or involves mediastinal structures 
*Note: Central compartment soft tissue includes prelaryngeal strap muscles and 
subcutaneous fat 
Regional lymph nodes (N) 
Nx: Regional lymph nodes cannot be assessed 
N0: No regional lymph node metastasis 
N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension 
N2: Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 
6 cm in greatest dimension; or in multiple ipsilateral lymph nodes, not more than 
6 cm in greatest dimension; or in bilateral or contralateral lymph nodes, not more 
than 6 cm in greatest dimension 
N2a: Metastasis in a single ipsilateral lymph node more than 3 cm but not more than 6 
cm in greatest dimension 
N2b: Metastasis in multiple ipsilateral lymph nodes, not 
more than 6 cm in greatest dimension 
N2c: Metastasis in bilateral or contralateral lymph nodes, 
not more than 6 cm in greatest dimension 
N3: Metastasis in a lymph node, more than 6 cm in greatest dimension 
Distant metastasis (M) 
M0: No distant metastasis 
M1: Distant metastasis 
Anatomic stage/prognostic groups 
0: Tis N0 M0 
I: T1 N0 M0 
II: T2 N0 M0 
III: T3 N0 M0, T1-T3 N1 M0 
IVA: T4a N0 M0, T4a N1 M0, T1-T3 N2 M0, T4a N2 M0 
IVB: Any N M0, Any T N3 M0 
IVC: Any T Any N M1 
Table 1. American Joint Committee on Cancer (AJCC) TNM classification of 
hypopharyngeal cancer  
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Several pathologic factors have been demonstrated to impact upon outcome in surgical 
treatment of hypopharyngeal cancer (Hall et al., 2009; Lee et al., 2008; Mochiki et al., 2007). 
Several studies reported the adverse impact of advanced stage, (Dinshaw et al., 2005; Hall et 
al., 2009; Lee et al., 2008; Mochiki et al., 2007), nodal extracapsular extension (Vandenbrouck 
et al., 1987; Lee et al., 2008), perineural invasion (Bova et al., 2005), and lymphovascular 
invasion (Bova et al., 2005; Mochiki et al., 2007). Increasing pathological nodal stage (Chu et 
al., 2008; Hall et al., 2009; Mochiki et al., 2007), and quality of tumour clearance were also 
revealed as significant prognostic factors (Gupta et al., 2010; Nishimaki et al., 2002).  
Tumour volume is the most important prognostic factor of treatment outcome for patients 
with advanced hypopharyngeal cancer treated with concurrent chemoradiotherapy and 
should always be taken into consideration in treatment planning (Plataniotis et al., 2004; 
Tsou et al., 2006). Thus, confirming the significance of gross tumour volume as the only 
independent prognostic factor for treatment outcome, Chen et al. (Chen et al., 2009) 
concluded that pretreatment CT-based gross tumour volume measurements could be 
considered as strong predictor of local control and survival in patients with advanced stage 
hypopharyngeal cancers treated with concurrent chemoradiotherapy. For this patients 
category, low pretreatment hemoglobin level (Lee et al., 1998; Prosnitz et al., 2005) and age 
older than 70 years (Pignon et al., 2009) were revealed as negative prognostic factors.  
6. Treatment of hypopharyngeal cancer  
6.1 Treatment of small lesions (T1N0-1 and small T2N0)  
Early-stage hypopharyngeal cancers include most T1N0-1 and small T2N0 cancers that do 
not require total laryngectomy. Patients with small lesions of the hypopharynx constitute 
approximately 20% of all patients presenting with hypopharyngeal cancer (Spector et al., 
2001). Conservation surgery or radiotherapy alone are considered effective treatment 
modalities for patients who present with T1N0-1 and selected T2N0 obtaining satisfactory 
rates of local control while optimising functional outcome (Allal, 1997; Jones et al., 1994; 
Jones & Stell, 1991). However, discrepancies exist among different authors in the choice of 
treatment approach for early hypopharyngeal lesions. Thus, some authors advocate 
conservation surgery with or without postoperative radiotherapy whereas other authors 
advocate radiotherapy alone. The study conducted by Groupe d’Etude des Tumeurs de la 
Tête et du Cou (GETTEC) (Foucher et al., 2009), supported conservation surgery procedures 
in patients with T1 or T2N0 hypopharyngeal lesions showing that transoral approach or 
partial pharyngolaryngectomy led to completely satisfactory results in terms of survival and 
locoregional control. Comparing the effect of surgery or radiotherapy in the treatment of 
postcricoid carcinoma, Axon et al. (Axon et al., 1997) recommended surgery as a better 
method of improving survival, especially in patients with no nodal disease. El Badawi et al. 
(El Badawi et al., 1982) reviewing patients with cancer of the pyriform sinus treated with 
radiotherapy, surgery, or surgery and postoperative radiotherapy, concluded that 
superficial lesions without vocal cord mobility impairment were suitable for definitive 
radiotherapy. Similar conclusion regarding the effectiveness of radiotherapy alone in the 
management of small tumours in the postcricoid area with no clinical evidence of neck 
lymph node metastasis was drawn by Stell et al. (Stell et al., 1982).  Levebvre & Lartigau 
(Levebvre & Lartigau, 2003), considering surgery and radiotherapy as approaches 
comparable in terms of local control and functional results in early hypopharyngeal cancer, 
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emphasized that the impressive improvement in radiotherapy techniques unequivocally 
enabled the acceptance of radiotherapy as an indisputable alternative to surgery. 
Furthermore, additional arguments supporting definitive radiotherapy as a treatment of 
choice for small hypopharyngeal tumours are the expected superior functional outcome 
(Freeman et al., 1979; Marks et al., 1978), the necessity for postoperative radiotherapy 
because of positive resection margin or extracapsular spread of nodal disease with its 
related morbidity following conservation surgery, and the need for elective irradiation of 
the lymph nodes in the neck when elective dissection had not been performed during the 
surgical procedure. The selection of patients for conservation surgical procedures or 
radiotherapy as a primary treatment modality must be carefully accomplished. Because of 
the lack of studies that analyse and compare the results of conservation surgery and 
definitive radiotherapy in terms of local control and functional outcome in patients with 
early hypopharyngeal cancers, the decision for adoption of one of these two treatment 
modalities should incorporate a complex assessment of the extent and volume of tumour 
and expected response to treatment modalities, patient age and physical status, patient 
preference including occupational considerations, patient compliance, prior head and neck 
malignancy, risk for second head and neck primary cancer, the ability to deliver an adequate 
radiotherapy, or the expertise of the surgical team to effectively realise conservation 
surgery, treatment cost, and physician and institutional bias. 
6.1.1 Surgery  
Summarising the results of surgery reported in published series, Levebvre (Levebvre, 2000) 
revealed that the treatment of early hypopharyngeal cancers with properly selected 
conservation surgical procedure provides a 5-year local control ranging between 90% and 
95% with a 5-year larynx function preservation ranging between 85% and 100%. For the 
small lesions of the pyriform sinuses, partial pharyngectomy or partial 
pharyngolaryngectomy should be considered. The indications for conservation surgery are 
represented by the absence of gross tumour involvement and impaired mobility of vocal 
cords and arytenoids, as well as by the absence of thyroid cartilage invasion and 
involvement of the apex of the pyriform sinus and postcricoid area (Freeman et al., 1979; 
Marks et al., 1978). Additionally, attention must be paid to the possible caudal, contralateral, 
and extralaryngeal extension, and soft tissue invasion. In selected patients with T1 and T2 
lesions of the medial wall of the pyriform sinus a supracricoid hemilaryngopharyngectomy 
is advocated (Freeman et al., 1979; Laccourreye et al., 1987). In patients with T1 and T2 
lesions of the lateral wall of the pyriform sinus, partial pharyngectomy through a lateral 
approach is indicated. Partial pharyngectomy through a transhyoid pharyngotomy, 
posterior pharyngectomy, or lateral pharyngotomy are conservation surgery procedures 
that allow the excision of T1 and small T2 lesions confined to the posterior wall of the 
hypopharynx. The lateral pharyngotomy as an approach that allows access to all subsites of 
the hypopharynx is also very suitable for small tumours of the posterior pharyngeal wall. 
Median labiomandibular glossotomy and transoral approach can also be employed for small 
lesions of the posterior pharyngeal wall. The reconstruction following excision of larger 
posterior wall lesions involves a free vascularised graft (Jol et al., 2003; Schwager et al., 
1999). Tumours arising in the postcricoid area are usually presented as advanced lesions. 
Surgical excision followed by postoperative radiation is the treatment of choice for cancers 
not amenable to a conservation protocol (i.e., tumours destroying cartilage, tumours too 
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bulky for control with primary radiation). The minimum operation recommended is total 
laryngectomy and partial pharyngectomy and pharyngoesophagectomy with reconstruction 
if extension into the esophagus is present. In several studies analysing the results obtained 
with partial surgery in patients with early cancer of the pyriform sinus the reported 5-year 
survival rates range between 47% and 83% (Barton, 1973; Chevalier et al., 1997; Laccourreye 
et al., 1993; Makeieff et al., 2004; Marks et al., 1978). Partial pharyngolaryngectomy also 
resulted in a 5-year local recurrence rate bellow 5% (Chevalier et al., 1997; Laccourreye et al., 
1993). In the retrospective study of Vandenbrouck et al. (Vandenbrouck et al., 1987), the 
reported rate of locoregional control was 89% in patients with T1 and T2 cancers of the 
pyriform sinus treated with conservation surgery. In the retrospective study of Pene et al. 
(Pene et al., 1978), primary surgery and postoperative radiotherapy in patients with early 
lesions of posterior pharyngeal wall (T1 and T2) resulted in 5-year survival rate of 30%. In 
the study of Jones et al. (Jones et al., 1995), the results of surgery and radiotherapy alone in 
patients with carcinoma of the postcricoid area showed no significant difference in the 
observed tumour-specific five-year survival rates between surgery and radiotherapy group. 
The transoral laser ednoscopic resection is a new conservation surgical approach suitable for 
T1 and T2 exophytic, highly differentiated squamous cell carcinomas of the upper part of 
the hypopharynx without extension to the apex of the pyriform sinus or to the postcricoid 
area (Glanz, 1999; Rudert & Hoft, 2003; Vilaseca et al., 2004). Few non-randomised studies 
evaluating transoral laser surgery in hypopharyngeal cancer reported 5-year overall 
survival rate of approximately 70% (Foucher et al., 2009; Rudert et al., 2003; Steiner et al., 
2001), and local control rate at 5 years ranging between 82% and 90% (Foucher et al., 2009; 
Steiner et al., 2001).  
Hypopharyngectomy by transoral robotic surgery as a procedure proposed to minimise the 
treatment-related morbidity following conventional surgical approaches for T1 or T2  
lesions arising in the pyriform sinus analysed in terms of efficacy and feasibility has been 
also shown to be a safe technique for the treatment of early hypopharyngeal cancer  
(Park et al., 2010).  
6.1.2 Radiotherapy  
The use of radiotherapy as a single treatment approach for small hypoharyngeal lesions 
(T1N0-1 and small T2N0) offers treatment for both the primary tumour and the neck, 
thereby obviating the need for neck dissections and their associated morbidity. Definitive 
radiotherapy could be considered as treatment of choice for non-circumferential postcricoid 
lesions allowing organ preservation and a reasonable probability of cure and restoration of 
swallow. Additionally, definitive radiotherapy could be effectively employed in patients 
who refuse surgery or who are poor surgical candidates because of underlying medical 
conditions.  
Several non-randomised controlled trials exploring the role of definitive radiotherapy in the 
treatment of early hypopharyngeal cancer, reported local control rates for T1 lesions arising 
from pyriform sinus ranging between 60% and 100% (Bataini et al., 1982; Mendenhall et al., 
1987a; Million & Cassisi, 1981). However, in the reported update of the University of Florida 
experience with early pyriform sinus cancer, the involvement of the apex of the pyriform 
sinus and the high probability for early cartilaginous involvement was shown to 
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significantly reduce local control for T1 lesions (Amdur et al., 2001). The rates of local 
control also decrease in bulky T2 lesions and in those larger than 2.5 cm (Pameijer et al., 
1998; Mendenhall et al., 1987b). The published data for hypopharyngeal sites other than 
pyriform sinus are more limited. Most of the studies reporting results of definitive 
radiotherapy in patients with carcinoma of the pharyngeal wall included lesions arising 
from both hypopharynx and oropharynx, and there is also a lack of randomised controlled 
trials exploring the role of definitive radiotherapy in early hypopharyngeal cancer arising in 
the postcricoid area. In the study of Fein et al. (Fein et al., 1993), the achieved 2-year local 
control rates for T1 and T2 pharyngeal wall cancer treated with definitive radiotherapy 
using conventional fractionation were 100% and 67%, respectively. Meoz-Mendez et al. 
(Meoz-Mendez et al., 1978) analysing the results of irradiation in the treatment of cancers of 
the pharyngeal walls emphasized that the recurrence rate at the primary site was associated 
with increasing T stage, while Talton et al. (Talton et al., 1981) considered radiotherapy as 
the most effective treatment in the posterior wall lesions. In a series of Farrington et al. 
(Farrington et al., 1986), a significant survival rate decrease in lesions of the postcricoid area 
more than 2 cm in length was observed following radiotherapy alone. The disease-free 
survival in patients who completed radiotherapy was 66% and 21% in stages I and II, 
respectively. In the study of Garden et al. (Garden et al., 1996), the observed 2-year local 
control rates in patients with early stage hypopharyngeal cancer from all sites treated with 
definitive radiotherapy were 89% for T1 lesions and 77% for T2 lesions. Nakamura et al. 
(Nakamura et al., 2006) reported 5-year local control rates of 85% and 65% for T1 and T2 
hypopharyngeal lesions. The observed overall survival at 5 years for stage I and II 
hypopharyngeal cancer from all sites treated by radiotherapy alone ranged between was 
40% and 78% (Pingree et al., 1987; Van Mierlo et al., 1995). In summary, primary 
conventionally fractionated radiotherapy for T1-2 hypopharyngeal cancers results in a 2-
year local control rate of 89-100% for T1 tumours and 60-70% for T2 tumours (Fein et al., 
1993; Garden et al., 1996; Van Mierlo et al., 1995). In order to improve local control rates in 
patients with early hypopharyngeal lesions treated with definitive radiotherapy, altered 
fractionation regimens were also explored by several authors. It was shown that 
hyperfractionation and accelerated fractionation significantly improve the local control of 
hypopharyngeal cancers of T2 or greater, and possibly also for T1 tumours. (Fu et al.,  2000; 
Garden et al., 1996 ; Niibe et al., 2003 ; Parsons et al., 1984 ; Rosenthal & Ang, 2004).  
The employment of postoperative radiotherapy is recommended in the presence of 
microscopically involved surgical margins being a pathological feature predicting a high-
risk for local recurrence (Cooper et al., 1998). Postoperative concurrent chemoradiotherapy 
is recommended in the presence of multiple high-risk factors represented by close or 
positive margins of resection, lymphatic and vascular embolism, perineural infiltration, and 
cartilage invasion (Bernier et al., 2004; Cooper et al., 2004).  
6.1.3 Neck management 
Neck management in patients with early hypopharyngeal cancer is also indicated because of 
the high risk of lymph node metastases (Layland & Sessions, 2005). Elective neck irradiation 
and elective neck dissection including retropharyngeal nodes are equally and highly 
effective in managing subclinical neck disease providing regional control of more than 90% 
(Ambrosch et al., 2001; Bataini, 1993; Pillsbury et al., 1997). Neck lymph node dissection 
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should be performed according to the definitions of the American Academy of 
Otolaryngology Head and Neck Surgery (AAOHNS) (Robbins et al., 2008). In patients with 
clinically negative neck, ipsilateral selective neck dissection for lateralised lesions or bilateral 
selective neck dissection for midline lesions of levels II, III, IV is performed. Neck dissection 
in clinically N0 patients represents a procedure that has therapeutic value by removal of 
occult metastatic disease. Neck dissection identifies subclinical nodal disease and, based on 
pathologic staging, allows the selective use of postoperative concurrent chemoradiotherapy 
in cases with pathologically proven multiple metastases or nodal extracapsular extension 
(Pillsbury et al., 1997; Clayman & Frank, 1998). Nodal disease in patients with clinically 
positive neck (N1) is treated with ipsilateral or bilateral radical neck dissection that refers to 
the removal of all lymph nodes from levels I through V. Retropharyngeal nodes could be 
also resected at the time of partial pharyngectomy in patients with radiographic evidence of 
metastases in this lymph node group. Investigating the significance of dissection of 
retropharyngeal nodes in hypopharyngeal cancer, Kamiyama R et al. (Kamiyama et al., 
2009) concluded that in order to improve prognosis, this dissection should be recommended 
at the time of primary surgical treatment in cancers whose primary subsites are posterior 
wall or pyriform sinus.  
Patients with clinical N0 disease are eligible for elective radiotherapy of the neck 
encompassing bilateral lymph nodes in levels II, III and IV. Elective treatment of level VI is 
indicated for patients with cancer of the pyriform sinus (particularly those located in the 
apex) and postcricoid area, and for those with esophageal involvement. Elective treatment 
of the retropharyngeal lymph nodes is indicated for cancer of the posterior pharyngeal wall 
or postcricoid area, and for those with invasion of the posterior pharyngeal wall from other 
sites (Gregoire et al., 2003). The determination of the target volume of elective radiotherapy 
of the neck should follow the consensus guidelines developed by the European 
Organization for Research and Treatment of Cancer/Radiation Therapy Oncology 
Group/Danish Head and Neck Cancer Group (EORTC/RTOG/DAHANCA) (Gregoire et 
al., 2003). According to the recommendations given by Gregoire et al. (Gregoire et al., 2006) 
for selection and delineation of the levels of lymph nodes for elective irradiation in patients 
with clinically positive neck and in those with positive neck nodes determined in the 
surgical specimen following neck dissection, the levels that should be electively treated are 
I, II, III, IV, V and retropharyngeal nodes, and level VI for esophageal extension. 
Retrostyloid space should be also included in cases with positive lymph node in Level II 
whereas supraclavicular fossa should be electively irradiated if there were positive nodes in 
level IV or V. Given the radiotherapy as primary treatment approach in patients with 
positive lymph node smaller than 3 cm (N1), it should be mentioned that although there are 
data from the literature showing that using conventional fractionation, regional control 
could be achieved in 75%-90% of cases (Bataini et al., 1990; Mendenhall et al., 1984; Taylor et 
al., 1991), some authors reported lower rates of regional control observed in their studies. 
Thus, in the study of Johansen et al. (Johansen et al., 2000), definitive radiotherapy resulted 
in 5-year regional control of 36% for N1 disease. Similar results were found in the 
retrospective review of patients with hypopharyngeal cancers treated with definitive 
radiotherapy performed by Gupta et al. (Gupta et al., 2009a) with 3-year locoregional 
control rate of 41% in patients with N1 disease.  
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6.2 Surgery and postoperative radiotherapy in locally-regionally advanced resectable 
lesions  
In order to improve outcome in patients with advanced stage resectable hypopharyngeal 
cancer (T2N1-3M0, T3-4N0-3M0), the role of postoperative radiotherapy following 
nonconservation surgery became a subject of analysis in many single-institution studies. An 
improvement in overall and disease-free survival was obtained in patients with locally-
regionally advanced hypopharyngeal cancer if combined treatment modality with radical 
surgery consisting of total laryngectomy, total or partial pharyngectomy and unilateral or 
bilateral neck dissection followed by radiotherapy was used. Thus, in the 1970s and 1980s, 
surgery (i.e., total laryngectomy and pharyngectomy with or without neck dissection) 
followed by postoperative radiotherapy was the standard form of therapy for advanced 
stage disease (Arriagada et al., 1983; Mirimanoff et al., 1985) with reported 5-year survival 
rates varying between 19% and 48% (Elias et al., 1995; Kim et al., 2001; Kraus et al., 1997; 
Lajtmam & Manestar, 2001; Pingree et al., 1987). Comparing the results of total 
pharyngolaryngectomy, neck dissection, and postoperative radiotherapy in patients with 
squamous cell carcinoma of the pyriform sinus with those obtained by surgery alone, El 
Badawi et al. (El Badawi et al., 1982) showed an increased locoregional recurrence rate after 
surgery alone (39%) as opposed to that following combined therapy (11%). In the analysis of 
Frank et al. (Frank et al., 1994) surgery and postoperative radiotherapy was found to 
improve survival in patients with advanced hypopharyngeal cancer. Survival rates at five 
years for postoperative radiotherapy group and for surgery alone group were 48% and 18%, 
respectively. Lee et al. (Lee et al., 2008) reported that total laryngectomy with partial or total 
pharyngectomy with unilateral or bilateral radical neck dissection and postoperative 
radiotherapy resulted in 3-year local control, disease-free survival, and overall survival rate 
of 44%, 44%, and 39%, respectively. However, there are some conflicting data in the 
literature regarding the role of adjuvant radiotherapy. Thus, Yates et al. (Yates et al., 1984), 
analysing the impact of addition of adjuvant radiotherapy following surgery on survival of 
patients with squamous cell carcinoma of the pyriform sinus, found that the surgery alone 
group demonstrated the best results with 5-year survival rate of 56% as compared to 33% for 
the groups treated with pre- or postoperative radiotherapy. Worse outcome in patients with 
hypopharyngeal cancer treated with surgery and postoperative radiotherapy as  
compared with those treated with surgery or radiotherapy alone was also found in the 
study of Pingree et al. (Pingree et al., 1987). The reported 5-year survival rates for 
 surgery alone, surgery and postoperative radiotherapy, and radiotherapy alone were  40%, 
32%, and 11%, respectively.   
The prognosis of patients with primary hypopharyngeal tumour and extensive and/or large 
lymph node metastases is highly determined by the N stage. Radiotherapy or surgery alone 
in the treatment of advanced nodal disease (N2-3) resulted in poor rates of regional control 
and survival (Gupta et al., 2009a; Johansen et al., 2000; Lou et al., 2008). In 1988, Teshima et 
al. (Teshima et al., 1988), analysing the results of radiotherapy in hypopharyngeal cancer 
with special attention paid to the nodal control, pointed out the role of postoperative 
radiotherapy in obtaining an effective nodal control for patients with clinically positive 
nodes. The use of postoperative radiotherapy following neck lymph node dissection is 
recommended for patients with N2 and N3 disease. Data from literature show improved 
regional control even in patients with very advanced nodal disease when postoperative 
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radiotherapy was used following radical neck dissection (Ambrosch et al., 2001; Lundahl et 
al., 1998; Richards & Spiro, 2000; Smeele et al., 2000). Postoperative radiotherapy in patients 
with resectable locally and/or regionally advanced hypopharyngeal cancer should be 
prescribed to the entire operative bed and draining nodes. The determination of the target 
volume of elective radiotherapy of the neck should follow the proposal for delineation of the 
nodal clinical target volume in the node positive and postoperative neck by Gregoire et al. 
(Gregoire et al., 2006) (see section 6.1.3). According to the European Society for Medical 
Oncology (ESMO) clinical recommendations for treatment of squamous cell carcinoma of 
the head and neck, the standard option for advanced resectable hypopharyngeal cancers is 
represented by surgery and postoperative radiotherapy in patients without high-risk 
pathological features found at surgery (Pivot & Felip, 2008). However, despite such radical 
therapy leading to the loss of natural speech function and impairment of swallowing ability 
with a consequent negative impact on the quality of life, cure rates for advanced disease 
remained low with reported 5-year survival rates varying between 20% and 50% 
(Beauvillain et al., 1997; Hoffman et al., 1998; Johansen et al., 2000; Kim et al., 2004; Lajtmam 
& Manestar, 2001).  
The confirmed negative influence of high-risk pathological features represented by surgical 
margins microscopically involved, extracapsular extension in positive lymph node, two or 
more positive lymph nodes, vascular embolism and perineural infiltration on patients 
outcome following surgery and postoperative radiotherapy (Ang et al., 2001), emerged the 
need for investigation of different treatment approaches including concomitant use of 
chemotherapy. Two similar, large-scale, postoperative randomised independent trials 
designed by the EORTC and RTOG were conducted to evaluate the role of high dose 
concurrent chemoradiotherapy in the postoperative treatment of high risk head and neck 
tumours (Bernier et al., 2004; Cooper et al., 2004). Both trials evaluated the role of 
concomitant cisplatin given every 3 weeks (100 mg/m2 on days 1, 22, 43) during 
radiotherapy course (Table 2). Retrospective analysis of data from both trials, revealed that 
extracapsular extension of nodal disease and/or microscopically involved surgical margins 
were the only risk factors for which the impact of concurrent chemoradiotherapy was 
significant in both trials (Bernier & Cooper, 2005). In 2004, National Cancer Institute (NCI) 
level I evidence for recommendation was established, because both studies demonstrated 
that adjuvant concurrent chemoradiotherapy was more efficacious with respect to 
radiotherapy alone in terms of locoregional control and disease-free survival (Bernier & 
Cooper, 2005). Currently, concurrent chemoradiotherapy with single agent platinum should 
be the gold standard for those patients found at surgery to have high-risk features 
(extracapsular extension and positive margins of resection) (Pivot et al., 2008). 
Based on the assumption that surgery may be a trigger of accelerated proliferation of 
remaining tumour cells, two phase III trials conducted to investigate the role of accelerated 
fractionation in the postoperative setting compared to conventionally fractionated 
postoperative radiotherapy (Ang et al., 2001; Sanguineti et al., 2005) failed to demonstrate 
any significant improvement of locoregional control and survival with accelerated 
postoperative radiotherapy. However, when in a phase III trial a weekendless continuous 
accelerated hyperfractionation postoperative radiotherapy (CHARTWEL) was employed in 
advanced squamous cell carcinoma of the oral cavity, larynx and hypopharynx who 
underwent radical surgery, the overall treatment time was shortened to only 12 days 
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compared with conventionally fractionated radiotherapy (Awwad et al., 2002). The data 
from this trial revealed significantly better 3-year locoregional control rate in the accelerated 
fractionation group than in the conventional fractionation group (88% and 57%, 
respectively) suggesting that accelerated proliferation could be considered an important 
determinant of treatment outcome. 
 
Trial DFS OS LRFR 
Bernier et al. (Bernier 
et al., 2004), 
(EORTC 22931) 
 
(5-year estimates) 
 
(5-year estimates) 
 
(5-year estimates) 
Experimental arm: 
Control arm: 
47%    (p=0.04) 
36% 
53%  (p=0.02) 
40% 
17%  (p=0.007) 
31% 
Cooper et al. (Cooper 
et al., 2004), 
(RTOG 9501) 
 
(2-year estimates) 
 
(2-year estimates) 
 
(2-year estimates) 
Experimental arm: 
Control arm: 
54%    (p=0.04) 
45% 
64%   (p=0.19) 
57% 
18%   (p=0.01) 
28% 
EORTC: European Organization for Research and Treatment of Cancer; DFS: disease-free survival; OS: 
overall survival; LRFR: locoregional failure rate; RTOG, Radiation Therapy Oncology Group 
Table 2. Comparative analysis of treatment outcome in EORTC trial 22931 and RTOG trial 
9501 
6.3 Definitive treatment for anatomic and functional organ preservation in locally-
regionally advanced resectable lesions 
Primary definitive therapy in patients with advanced resectable hypopharyngeal cancers 
requiring total laryngectomy and partial or total pharyngectomy can also be realised with 
treatment modalities allowing organ preservation. Strategies employed to increase 
locoregional control and survival attempting at the same time to achieve anatomic and 
functional organ preservation include concurrent chemoradiotherapy, altered fractionation 
radiotherapy, intensified radiotherapy regimens in combination with chemotherapy, 
induction chemotherapy followed by radiotherapy, and targeted therapy using cetuximab. 
Concurrent drug-enhanced radiotherapy i.e. concurrent chemoradiotherapy (in relatively 
healthy patients) and altered fractionation radiation regimens (in relatively unfit patients), 
are considered best established as organ preservation approaches for cancers arising from 
hypopharynx and other sites in the head and neck region (Adelstein et al., 2000; Forastiere et 
al., 2001a; Fu et al., 2000; Koch et al., 1995; Pignon et al., 2000).  
6.3.1 Concurrent chemoradiotherapy 
Concurrent chemoradiotherapy as definitive treatment for advanced head and neck cancers 
including those arising from the hypopharynx has been studied in the past 15 years. 
However, due to the low incidence, hypopharyngeal cancers grouped with other head and 
neck cancers usually represented only smaller subgroups with details of their treatment 
being rarely specifically reported (Tai et al., 2008; Robson, 2002). The rarity of this disease, 
and the time needed for data collection could be accepted as an explanation for the absence  
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of multicenter randomised clinical trials undertaken to evaluate the role of concurrent 
chemoradiotherapy in the treatment of advanced hypopharyngeal cancer. In 1990 Sanchiz 
et al. (Sanchiz et al., 1990) reported the results of a prospective randomised trial on 859 
patients with advanced head and neck cancer including those having hypopharynx as a 
primary site. Patients were randomly assigned to receive conventionally fractionated 
radiotherapy, radiotherapy with standard fractionation with concomitant use of 5-
fluorouracil or hyperfractionated radiotherapy. Significant improvement in survival 
compared with the group treated with conventional fractionation was obtained in groups 
treated either with concurrent chemoradiotherapy or altered fractionation (Table 3). 
Adelstein et al. (Adelstein et al., 2000) reported a single institution trial that enrolled 100 
patients with stages III and IV squamous cell head and neck carcinoma. Patients were 
randomly assigned to receive conventionally fractionated radiotherapy alone or with 
concurrent chemotherapy consisting of two cycles of cisplatin and 5-fluorouracil. Planned 
neck dissection was encountered for patients with N2 and N3 disease. A significant  
improvement in the rates of local control (77% vs. 45%, p < 0.001), distant metastasis-free 
survival (84% vs. 75%, p = 0.09), and 5-year recurrence-free survival (62% vs. 51%, p = 
0.04) was obtained with concurrent chemoradiotherapy (Table 3). The superiority of 
concurrent chemoradiotherapy in the improvement of overall survival in patients with 
advanced head and neck cancer has been confirmed in several meta-analyses (Browman et 
al., 2001; El-Sayed & Nelson, 1996; Munro, 1995; Pignon et al., 2000). The results of meta-
analysis reported by Munro (Munro, 1995), and the results of meta-analysis of El-Sayed 
and Nelson (El-Sayed & Nelson, 1996) showed a statistically significant improvement in 
survival for chemotherapy given concurrently with radiotherapy. The largest meta-
analysis performed by the Meta-Analysis of Chemotherapy on Head and Neck Cancer 
(MACH-NC) Collaborative Group and published by Pignon et al. (Pignon et al., 2000) in 
2000, evaluated individual patient data from 63 randomised trials excluding trials on 
nasopharyngeal carcinoma. This meta-analysis confirmed the superiority of the overall 
use of chemotherapy with 5% improvement in 5-year overall survival with highest 
increase in survival with use of concurrent chemoradiotherapy (8% at 5-years; p < 0.0001). 
There was also an evident benefit when cisplatin was used in the combined approach. In 
patients over 70 years the benefit was less evident. In the updated meta-analysis 
published in 2004 (Bourhis et al., 2004), 24 new trials, most of them on concurrent 
chemoradiotherapy, were included totalising 87 trials and 16,000 patients. The update 
confirmed survival benefit of 8% at 5 years (p < 0.0001) of concurrent chemoradiotherapy. 
This updated analysis also confirmed the higher magnitude of the benefit for platinum-
based chemotherapy. A decreasing effect of chemotherapy with age was also shown (p = 
0.01). The overall survival gain was better for concurrent chemoradiotherapy with altered 
fractionation compared with concurrent chemoradiotherapy with conventional 
fractionation, indicating that alteration of fractionation might boost the effect of 
chemoradiotherapy. In the meta-analysis conducted by Browman et al. (Browman et al., 
2001), only platinum-based chemotherapy given concomitantly with radiotherapy was 
found highly significant in overall survival improvement (p < 0.0001). The German meta-
analysis suggested that, considering only concurrent chemoradiotherapy without 
prolonged overall treatment time, an absolute survival gain of 13% to 15% at 2 years with 
respect to conventional radiotherapy can be obtained (Budach et al., 2006). The extensive 
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research of the influence of the addition of chemotherapy to radiotherapy on overall 
survival resulted in confirmation that only concurrent chemoradiotherapy as definitive 
treatment for patients with locoregionally advanced head and neck cancer including those 
with advanced hypopharyngeal cancer has succeeded to improve outcomes. Thus, 
evidence based medicine has shown that concurrent chemoradiotherapy without 
prolongation of overall treatment time and including cisplatin only or cisplatin-5-
fluorouracil should be considered the treatment of choice for patients who fit 
chemotherapy (National Cancer Institute [NCI] level 1 of evidence supporting 
recommendation) (Corvo, 2007). 
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Nh: number of patients with hypopharyngeal cancer; fx: fraction, d: day, wk: per week; 5-FU: 5-
fluorouracil; i.v.: intravenously; OS: overall survival; n.s.: not significant; RT: radiotherapy; LRC: 
locoregional control; RFS: recurrence-free survival; DMFS: distant metastases-free survival; DSS: 
disease-specific survival; LV: leucovorin; LRPFS: locoregional progression-free survival; PFS: 
progression-free survival; SLC: survival with local control  
Table 3. Randomised studies comparing concurrent chemoradiotherapy with radiotherapy 
alone in patients with advanced head and neck cancer 
Regarding the question about the number of drugs that can be added to radiotherapy and 
the timing of drug delivery once must be admitted that the optimum regimen is not yet 
known. The most common method used was delivery of drugs every 3 weeks (Adelstein et 
al., 1997; Adelstein et al., 2000) with the most frequently used regimen being the one 
proposed by Adelstein et al. (Adelstein et al., 2003) based on three courses of cisplatin every 
3 weeks (100 mg/m2 on days 1, 22, and 43) (Table 3). Weekly (Gupta et al., 2009b), or daily 
(Jeremic et al., 1997; Jeremic et al., 2000) administration of single-agent cisplatin has been 
also studied. According to the results of the meta-analysis of the MACH-NC Collaborative 
Group, platinum-based chemotherapy was more effective than non-platinum containing 
regimens, but multiagent therapy was not better than single agent. The superiority of 
platinum-based chemotherapy has been also confirmed in the meta-analysis of Browman et 
al. (Browman et al., 2001). According to Pignon et al. (Pignon et al., 2005), clinical benefit 
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might be obtained even with a total dose of cisplatin of only 200 mg given in different 
timing concurrently with radiotherapy. Preliminary results from Radiation Therapy 
Oncology Group (RTOG) 97-03 three-arm randomised phase II trial enrolling patients with 
stage III or IV squamous carcinoma of the oral cavity, oropharynx, or hypopharynx revealed 
that concurrent radiotherapy and two-drug chemotherapy using either paclitaxel plus 
cisplatin, 5-fluorouracil plus cisplatin, or hyroxiurea plus 5-fluorouracil was feasible 
(Garden et al., 2004a). However, there was no phase III trial performed to show taxane-
based concurrent chemoradiotherapy to be superior to radiotherapy alone, and no 
randomised trial has demonstrated a taxane, either as a single agent or in combination with 
other drugs to be superior to single-agent, platinum-based concurrent chemoradiotherapy.  
6.3.2 Altered fractionation radiotherapy 
Another approach focused on improvement of locoregional control and organ preservation 
in patients with locally advanced head and neck cancer was the investigation of 
modification of conventionally fractionated radiotherapy. Two prototypes of altered 
radiation fractionation regimens (hyperfractionation and accelerated fractionation) have 
been tested in retrospective and randomised trials for the last three decades. Promising 
improvements in locoregional control with the use of altered fractionated radiation 
schedules in the treatment of advanced head and cancer were demonstrated in several 
single-institution studies (Parsons et al., 1993; Wang et al., 1985). On the contrary, a 
retrospective study of Garden et al (Garden et al., 1995) did non reveal statistically 
significant differences in local control rates and survival rates between patients with 
carcinoma of the larynx or hypopharynx treated with conventional fractionation and those 
irradiated with hyperfractionation. However, only small number of studies referred on the 
role of altered fractionation exclusively in patients with advanced hypopharyngeal cancer. 
In one of those studies in which conventional radiotherapy was compared with 
hyperfractionated radiotherapy, multivariate analysis showed that twice-daily fractionation 
was the most important treatment-related variable in patients with squamous cell carcinoma 
of the pharyngeal wall (Fein et al., 1993). Retrospectively analising the results of definitive 
radiotherapy in patients with hypopharyngeal cancer, Antognoni et al (Antognoni et al., 
1991) did not show any impact of fractionation regimen on patients outcome. On the 
contrary, in the retrospective study on 52 patients with hypopharyngeal carcinoma, 
significantly better 5-year survival rate was obtained with accelerated hyperfractionation 
(44%) than with conventional fractionation (12%) (Akimoto et al., 1996).  
The largest prospective randomised trial undertaken to compare standard fractionation 
radiotherapy against hyperfractionation and accelerated fractionation with split course and 
accelerated radiotherapy with concomitant boost in the management of patients with 
advanced head and neck squamous cell carcinoma was RTOG trial 9003 (Fu et al., 2000). The 
results of this four-arm trial of 1073 patients with locally advanced head and neck cancer, 
showed that the locoregional control was significantly increased by increase of the total dose 
without changing the overall time using hyperfractionation (2-year locoregional control 
54.4% with hyperfractionation vs. 46% with conventional fractionation, p = 0.045) without 
increase in overall survival. The results also revealed that accelerated fractionation with 
concomitant boost yielded a significantly better locoregional control than standard 
radiotherapy (2-year locoregional control 54.5% with accelerated fractionation with 
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concomitant boost vs. 46% with conventional fractionation, p = 0.05) and a trend toward 
improved disease-free survival (2-year disease-free survival 39% with accelerated 
fractionation with concomitant boost vs. 32% with conventional fractionation, p = 0.054). 
Concerning the treatment related toxicity, hyperfractionation induced more severe acute 
mucositis compared to the conventional fractionation arm, and accelerated fractionation 
with concomitant boost-arm had significantly higher grade 3 or worse acute side effects (p < 
0.0001) and significantly increased grade 3 or worse late side effects (p < 0.011). It should be 
pointed out that this most important randomised trial was not site specific to the 
hypopharynx. Results of recently published randomised controlled clinical study of 
accelerated fractionation performed by the national Swedish group including 750 patients 
with squamous cell carcinoma of the oral cavity, oropharynx, larynx and hypopharynx did 
not prove that accelerated radiotherapy was more efficacious compared with conventional 
radiotherapy in terms of both locoregional control and overall survival (Zackrisson et al., 
2011). This randomised trial was also not site specific to the hypopharynx. 
Meta-analysis undertaken by Meta-Analysis of Radiotherapy in Carcinomas of the Head 
and Neck (MARCH) Collaborative Group (Bourhis et al., 2006) and aimed to assess whether 
different types of altered fractionated radiotherapy in head and neck squamous cell 
carcinoma could improve survival compared with conventional radiotherapy, included 
findings of 15 trials with 6,515 patients. This meta-analysis of updated individual patient 
data showed an improvement of 6.4% of locoregional control (from 46% to 53%, p < 0.0001), 
and an improvement of 3.4% of overall survival (from 36% to 39%, p < 0.03) with altered 
fractionation. The benefit in overall survival was significantly higher with 
hyperfractionation regimen (8% at 5 years) than with accelerated radiotherapy. The 
advantage of hyperfractionation was also confirmed in the German meta-analysis by 
Budach et al (Budach et al., 2006). The findings of this meta-analysis based on published 
data suggested that, among different types of altered radiotherapy, hyperfractionation 
obtained better 2-year overall survival than conventional radiotherapy with a significant 
benefit of 12 months (p < 0.001). According to the results of randomised trials exploring 
altered fractionation regimens and considering the results of the two meta-analyses, 
evidence based medicine showed that acceleration of radiation of one week without dose 
reduction and hyperfractionation are consistently better than conventional fractionation for 
locoregional control of intermediate to advanced carcinomas without an increase in late 
toxic effects (National Cancer Institute [NCI] level 1 of evidence supporting 
recommendation). 
6.3.3 Intensified radiotherapy regimens in combination with chemotherapy 
Altered fractionated radiotherapy with concurrent chemotherapy has been also evaluated. 
In a phase II study at a single institution conducted by Prades et al. (Prades et al., 2002), 
there were no statistically significant differences observed in overall and disease-free 
survival between patients with pyriform sinus cancer treated with accelerated radiotherapy 
alone and those treated with intensified concurrent chemoradiotherapy. In a single 
institution phase II trial exploring organ preservation using split hyperfractionated 
accelerated radiation therapy and concomitant cisplatin in patients with advanced cancer of 
the larynx and hypopharynx, De la Vega et al. (De la Vega et al., 2003) found organ 
preservation possible in 44% of patients. The encouraging results of RTOG phase II trial 99-
14 conducted to evaluate the accelerated radiotherapy using concomitant boost combined 
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with two cycles of concurrent cisplatin in patients with stage III and IV squamous cell 
carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx (Ang et al., 2005) 
suggesting that intensified radiotherapy regimens could be combined safely with 
chemotherapy motivated a phase III trial (RTOG H0129) predicted to determine whether 
accelerated fractionation using concomitant boost plus cisplatin can lead to better results 
compared with conventionally fractionated radiotherapy in combination with concurrent 
use of cisplatin.  
Several randomised trials exploring intensified radiotherapy regimens in combination with 
chemotherapy in advanced head and neck cancer included patients with hypopharyngeal 
cancer (Brizel et al., 1998; Budach et al., 2005; Huguenin et al., 2004; 2004; Jeremic et al., 2000; 
Staar et al., 2001; Wendt et al., 1998) (Table 3). In a single institution study reported by Brizel 
et al. (Brizel et al., 1998) better locoregional control was achieved by concurrent 
chemoradiotherapy without any improvement in overall survival (Table 3). Wendt et al. 
(Wendt et al. 1998) reporting the results of a regimen consisting of split-course altered 
fractionation plus chemotherapy concluded that concurrent chemoradiotherapy offered 
significantly improved 3-year locoregional control and overall survival rate with acute 
reactions more pronounced in the concurrent chemoradiotherapy arm (Table 3). In a study 
of hyperfractionation, Jeremic et al. (Jeremic et al., 2000) reported a significant improvement 
in 3-year locoregional control, overall survival and distant-metastases-free survival with 
hyperfractionated radiotherapy and concurrent low-dose daily cisplatin as compared with 
hyperfractionation alone (Table 3). The reported frequency of acute mucositis and late 
complications were similar in both arms. The improvement of therapeutic index of 
hyperfractionated radiotherapy by concomitant cisplatin has been also confirmed in the 
randomised trial conducted by Huguenin et al. (Huguenin et al., 2004). In the multicentric 
randomised German trial conducted by German Cooperative Group (Staar et al., 2001), a 
concomitant boost accelerated fractionation alone was compared with the same 
radiotherapy regimen plus carboplatin and 5-fluorouracil (Table 3). The authors concluded 
that the efficiency of intensified concurrent chemoradiotherapy was less then expected when 
compared to radiotherapy alone. Updated results of this trial have shown no improvement 
in locoregional failure-free survival and overall survival among patients with 
hypopharyngeal cancer treated with intensified regimen (Semrau et al., 2006). Reporting 
final results of a prospective randomised study in locally advanced head and neck cancer 
comparing concurrent 5-fluorouracil and mitomycin chemotherapy and hyperfractionated 
accelerated radiotherapy to hyperfractionated accelerated radiotherapy alone, Budach et al. 
(Budach et al., 2005) have shown a locoregional control and survival benefit when  
altered fractionation in combination with chemotherapy was used without any efficacy 
benefit revealed in patients with advanced hypopharyngeal cancer (Table 3). It must be 
emphasized that in patients with advanced cancer of the hypopharynx intensified 
radiotherapy regimens in combination with chemotherapy currently do not represent a 
routinely recommended treatment. 
6.3.4 Adjuvant neck dissection following concurrent chemoradiotherapy 
General consensus exists that adjuvant neck dissection is not necessary for patients with N1 
disease who have complete response to concurrent chemoradiotherapy in the neck. 
Although it has been shown that concurrent chemoradiotherapy provided good regional 
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control even in patients with advanced N-stage disease, there was an increased risk of 
residual disease observed with the increased stage of nodal disease (Boyd et al., 1998) with 
residual tumour found in approximately one third of the surgical specimens when treatment 
included planned neck dissection following chemoradiotherapy (Haraf et al., 1991; 
Sanguineti et al., 1999). Randomised studies addressing the question of best approach for 
patients who achieved a clinical complete response after concurrent chemoradiotherapy for 
initial N2 or N3 disease are lacking. Although regional control remained higher with 
adjuvant neck dissection following hyperfractionated or accelerated radiotherapy regimens 
(Mendenhall et al., 2002) the role of adjuvant neck dissection following concurrent 
chemoradiotherapy for patients with N2 or N3 disease is controversial (Brizel et al., 2004; 
Grabenbauer et al., 2003). Current recommendations range from planned neck dissection for 
all patients with pretreatment N2 or N3 disease to neck dissection only in patients with 
radiographic or clinical evidence of residual disease. Adjuvant neck dissection should be 
performed 6 to 10 weeks after completion of concurrent chemoradiotherapy. The avoidance 
of expected increased treatment related morbidity should be obtained by performing 
modified or selective dissections with removal of nodes only from levels II-IV.   
6.3.5 Induction chemotherapy 
Several studies were performed to evaluate the role of induction chemotherapy followed by 
definitive radiotherapy in obtaining functional organ preservation in advanced resectable 
hypopharyngeal cancer. The general approach was that patients were given two to three 
cycles of induction chemotherapy followed by definitive radiotherapy, with surgery 
reserved for nonresponse to induction chemotherapy, persistent disease after radiation, or 
relapse. Results of retrospective studies on patients with resectable, locally advanced 
hypopharyngeal cancers requiring total laryngectomy treated with one to three cycles of 
induction cisplatin-based chemotherapy followed by definitive radiotherapy in the presence 
of complete or partial response to chemotherapy at the primary site have shown a rate of 
larynx preservation ranging between 32% and 52% (Kim et al., 1998; Kraus et al., 1994; 
Zelefsky et al., 1996). Comparing results regarding locoregional control, disease-free 
survival, and overall survival achieved with this treatment approach with results obtained 
with surgery and postoperative radiotherapy in patients with similarly staged disease, it has 
been suggested that induction chemotherapy followed by definitive radiotherapy could be 
considered an effective strategy to achieve organ preservation without compromising 
survival in patients with advanced cancer of the hypopharynx (Kim et al., 1998).  
There were few randomised phase III studies conducted on patients with hypopharyngeal 
cancers eligible only for total laryngectomy with partial pharyngectomy, comparing surgery 
and postoperative radiotherapy with two or three cycles of induction cisplatin/5-
fluorouracil chemotherapy followed by radiotherapy in clinically complete responders, or 
total laryngectomy for those who had not a complete response (Lefebvre et al., 1996), or 
induction chemotherapy plus radiotherapy with induction chemotherapy plus surgery plus 
radiotherapy (Beauvillain et al., 1997), or induction chemotherapy followed by radiotherapy 
with concurrent chemoradiotherapy (Prades et al., 2010). In the randomised phase III study 
24891 conducted by EORTC, survival did not differ between treatment groups and 
functional larynx was retained in 50% of the survivors in the chemoradiotherapy group 
(Lefebvre et al., 1996). The results from this trial were confirmed by its long term evaluation 
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(Lefebvre et al., 2004). In the French randomised trial conducted by Beauvillian et al. 
(Beauvillain et al., 1997), statistically improved 5-year local control and overall survival was 
found in patients treated with induction chemotherapy followed by total 
laryngopharyngectomy and postoperative radiotherapy. Larynx preservation was obtained 
in 38% of patients treated with induction chemotherapy followed by definitive 
radiotherapy. Nevertheless, several meta-analyses have failed to demonstrate any 
significant improvement in survival after induction chemotherapy followed by radiotherapy 
(Browman, 1994; El-Sayed & Nelson, 1996; Pignon et al., 2000). The largest and most 
detailed of these, the meta-analysis of the MACH-NC Collaborative Group, analysed data 
from 31 trials of induction chemotherapy with more than 5,200 patients enrolled, and 
reported 2% 5-year improvement in overall survival being statistically nonsignificant  
(p = 0.38) (Pignon et al., 2000).  
The renewed interest in induction chemotherapy arisen from data showing treatment failure 
due to the development of distant metastases in 1 of 5 patients with stage III-IV head and 
neck cancer treated with multimodality approaches including concurrent 
chemoradiotherapy (Bernier & Bentzen, 2003) led to the evaluation of the use of both 
induction chemotherapy and concurrent chemoradiotherapy in a sequential approach 
supposed to provide optimal benefit for this patients category. In the light of emerged need 
to improve overall treatment outcome in patients with locoregionally advanced head and 
neck cancer, the results of sequential therapy could be considered especially important for 
patients with advanced cancers of the hypopharynx because this primary site has been 
found to be an independent predictor for distant metastases development (Adelstein et al., 
2006a). Both randomised phase III studies performed to evaluate sequential therapy with 
induction chemotherapy, the TAX 324 study (Posner et al., 2007) and the study conducted 
by the investigators in Madrid (Hitt et al., 2005) confirmed the benefit of induction 
chemotherapy using a triplet combination including taxane followed by concurrent 
chemoradiotherapy. However, there would be no level 1 of evidence data showing the 
superiority of induction chemotherapy followed by concurrent chemoradiotherapy over 
concurrent chemoradiotherapy until ongoing randomised, phase III trials comparing 
sequential therapy versus concurrent chemoradiotherapy complete (Adelstein et al., 2006b; 
Posner, 2005).  
6.3.6 Targeted therapy with cetuximab 
Based upon the evidence of increased levels of Epidermal Growth Factor Receptor (EGFR) 
expression in the majority of head and neck cancer, and the associated poor outcome with 
its presence (Chung et al., 2006), the addition of molecular targeted therapies in head and 
neck cancer was assumed as another potential method offering further improve outcome. A 
large international multicenter randomised phase III clinical study was performed in which 
radiotherapy alone was compared with radiotherapy plus weekly cetuximab at an initial 
dose of 400 mg/m2 followed by 250 mg/m2 weekly for the duration of radiotherapy in 
patients with stage III-IV cancer of the oropharynx, larynx or hypopharynx (Bonner et al., 
2006). In this study, radiotherapy was delivered either with conventional fractionation or 
with altered fractionation (hyperfractionation or concomitant boost accelerated 
radiotherapy). The median survival, and the observed rates of locoregional control and 
overall survival at 3 years were significantly higher in patients treated with radiotherapy 
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plus cetuximab than those in patients treated with radiotherapy alone. However, the 
median duration of overall survival for patients with hypopharyngeal cancer was equal in 
both treatment groups. Reporting the 5-year survival data from this study, Bonner et al. 
(Bonner et al., 2010) showed significantly improved overall survival at 5 years for patients 
treated with cetuximab and radiotherapy compared with that achieved in the radiotherapy-
alone group. The results from this prospective randomised trial support the superiority of 
concurrent targeted antibody enhanced radiotherapy over radiotherapy alone for advanced 
disease (NCI level of evidence Iii A for a single phase III trial, level 2 for recommendation). 
It has been suggested that it is reasonable to consider this regimen of radiotherapy plus 
cetuximab in patients with coexisting medical conditions and poor performance status who 
are not good candidates for concurrent chemoradiotherapy or surgery (Garden et al., 2004b; 
Seiwert & Cohen, 2005).  
6.4 Unresectable M0 disease 
The published guidelines by the National Comprehensive Cancer Network (NCCN) for 
technical unresectability criteria including evidence for direct invasion of cervical vertebrae 
or brachial plexus and direct involvement of deep muscles of the neck or carotid artery, 
provided a general framework to clearly define tumours being unresectable if anatomic 
considerations make it unlikely that all gross tumour can be removed or that local control 
can be achieved after resection even with the addition of postoperative radiotherapy 
(Forastiere et al., 2005). Patients presenting with unresectable hypopharyngeal cancer 
without evidence of distant metastases may be considered appropriate for localised and 
systemic treatment. However, historically speaking, conventionally fractionated 
radiotherapy offering low probability of cure was considered palliative when used as a 
single treatment modality in patients with unresectable disease.  In order to improve 
locoregional control and to influence on prolongation of survival, the integration of 
chemotherapy with radiotherapy has been used as multimodality treatment approach for 
unresectable disease (Vokes & Weichselbaum, 1990). Induction chemotherapy with rare 
exception has not been shown to improve survival in patients with unresectable disease. A 
benefit from induction chemotherapy in term of overall survival has been suggested in the 
subset analysis of inoperable patients in the large study by Paccagnella et al. (Paccagnella et 
al., 1994). The subset analysis of the updated results for overall survival after a minimum 
follow-up of 10 years reported by Zorat et al. (Zorat et al., 2004) showed that among 
inoperable patients, there was a statistically significant better survival observed in the 
induction chemotherapy group compared to patients who did not receive induction 
chemotherapy. The EORTC 24971/TAX 323, a phase III study of 358 patients with 
unresectable locoregionally advanced head and neck cancer showed that the addition of 
docetaxel to cisplatin and 5-fluorouracil for induction and given before radiotherapy 
improved both progression-free and overall survival with less toxicity compared to cisplatin 
and 5-fluorouracil induction chemotherapy (Vermorken et al., 2007). Analysing the results 
of EORTC 24971/TAX 323 study in terms of symptom control and quality of life, Van 
Herpen et al. (Van Herpen et al., 2010) revealed that induction chemotherapy with docetaxel, 
cisplatin and 5-fluorouracil followed by definitive radiotherapy not only improved survival 
and reduced toxicity compared with cisplatin plus 5-fluorouracil based induction 
chemotherapy, but also had a substantial impact on improvement of quality of life in 
patients with unresectable locoregionally advanced disease. Randomised phase II studies 
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 comparing concurrent cisplatin-based chemoradiotherapy and induction chemotherapy 
followed by definitive radiotherapy in patients with unresectable head and neck cancer did 
not reveal any statistically significant difference in the overall survival between treatment 
groups, but taking into account the similar activity of two treatment schedules and the 
better compliance associated with the concurrent treatment, authors suggested that 
concurrent chemoradiotherapy might be considered an option in this patients category 
(Pinnaro et al., 1994; Taylor et al., 1994). In the Intergroup phase III study of Southwest 
Oncology Group (SWOG) and Eastern Cooperative Oncology Group (ECOG) for locally 
advanced and unresectable head and neck cancer, statistically significant difference in 
favour of concurrent chemoradiotherapy was observed only between cisplatin plus 
radiotherapy and radiotherapy alone (Adelstein et al., 2003). However, although 
randomised phase III trials comparing radiotherapy alone to concurrent chemoradiotherapy 
in advanced head and neck cancer were not specific for unresectable disease and 
hypopharyngeal primaries, the consistent improvement in locoregional control and survival 
obtained with concurrent chemoradiotherapy as well as the small, but consistent statistically 
significant benefit of this treatment modality revealed in the meta-analyses (Bourhis et al., 
2004; Pignon et al., 2000) led to recommendation supporting radiotherapy and concurrent 
cisplatin-based chemoradiotherapy as standard treatment for patients with unresectable 
hypopharyngeal cancers. Recently reported definitive results of a phase III prospective 
multicenter randomised study conducted in Italy in which 164 patients with unresectable 
head and neck cancer were randomised to receive radiotherapy alone or combined with 
daily low-dose carboplatin showed statistically significant improvement in 3, 5 and 10-year 
overall survival rates in the group treated with concurrent chemoradiotherapy (Ruo Redda 
et al., 2010). In the absence of conclusive arguments supporting exact schedule of cisplatin 
administration, a nonrandomised study was conducted to compare two courses cisplatin or 
two courses of cisplatin plus 5-fluorouracil in 128 patients with locally advanced 
unresectable head and neck cancer. The results showed that two courses of fractionated 
cisplatin were accompanied with less acute toxicity whereas similar outcome and incidence 
of late toxicities were observed with both chemotherapy schedules (Tribius et al., 2009). The 
use of altered fractionation regimes in the management of unresectable, locoregionally 
advanced head and neck cancer have also been a part of an intensive clinical research 
focused on the improvement of locoregional control and overall survival. Based on the 
results of a large non–site-specific randomised RTOG 90-03 trial demonstrating an 
improvement in local control with accelerated fractionation using concomitant boost and 
hyperfractionated radiotherapy compared with conventional fractionation (Fu et al., 2000), 
and in accordance with the assessment of MARCH Collaborative Group (Bourhis et al., 
2006) showing statistically significant improvement in locoregional control and an 
improvement in overall survival achieved with the use of accelerated radiotherapy, and 
especially with hyperfractionated radiotherapy, altered fractionation has been 
recommended as an alternative to concurrent chemoradiotherapy in patients with 
unresectable head and neck cancer. Nevertheless, both concurrent chemoradiotherapy and 
altered fractionation are accompanied with increased rates of acute and late toxicity. 
Intensified radiotherapy regimens in combination with chemotherapy are not routinely 
recommended in patients with unresectable head and neck cancer. A TAX 324 randomised 
phase III trial (Posner et al., 2007) demonstrated significant advantage of cisplatin/5-
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fluorouracil/docetaxel induction chemotherapy followed by concurrent platinum based 
chemoradiotherapy in patients with advanced or unresectable head and neck disease 
including patients with hypopharyngeal cancer. However, despite the encouraging results 
observed with sequential therapy incorporating taxane in the induction chemotherapy 
setting, because of the lack of published data from phase III trials comparing induction 
chemotherapy followed by concurrent chemoradiotherapy with the standard treatment of 
concurrent chemoradiotherapy alone, this treatment approach in patients with unresectable 
hypopharyngeal cancer remains investigational. Besides induction chemotherapy followed 
by concurrent chemoradiotherapy, targeted therapy with cetuximab, tyrosine kinase 
inhibitor drugs, and the association of cetuximab with cisplatin-based concurrent 
chemoradiotherapy, also represent treatment approaches whose role in the management of 
unresectable hypopharyngeal cancer is yet to be established.  
6.5 Radiation techniques  
6.5.1 Two-dimensional (2D) radiotherapy  
In conventional 2D radiotherapy, treatment setup is customized using conventional 
simulator and the placement of the radiation fields and their shapes are based on the bony 
anatomy acquired by the simulator diagnostic-quality films. A shrinking field technique 
initiating with opposed pair of lateral fields and a low anterior field covering the 
postoperative bed in patients treated with postoperative radiotherapy, or the primary 
tumour and clinically positive neck nodes in patients treated with definitive radiotherapy, 
and subclinical disease in the neck nodes including node levels in accordance with the nodal 
status and the subsite and the extension of the primary tumour is used (see section 6.1.3).   
6.5.2 Three-dimensional (3D) conformal radiotherapy  
In 3D conformal radiotherapy, treatment planning CT scans are required to define and 
delineate gross tumour volumes (GTVs), and clinical target volumes (CTVs). Determination 
of postoperative treatment volumes (CTVs) is based on preoperative staging results, 
pathologic review of surgical specimens, operative findings, and postoperative clinical 
assessment (see section 6.1.3). In definitive radiotherapy, the GTV of the primary tumour 
and the metastatic lymph nodes is defined as any visible tumour and the gross nodal 
disease revealed on imaging studies and/or physical examination. The CTV encompasses 
the GTV plus a margin around the tumour for the potential microscopic extension of the 
disease according to anatomical barriers, and also includes node levels in the neck according 
to the nodal status as well as the subsite of the primary tumour (see section 6.1.3). The 
planning target volumes (PTVs) are obtained by adding a margin of 0.5 cm around the 
adequate CTVs. The definition of contoured volumes and organs of risk is as recommended 
by International Commission on Radiation Units and Measurements (ICRU) Report 62 
(International Commission on Radiation Units and Measurements [ICRU] Report 62, 1999). 
Delineation of the neck lymph node levels should be realised according to DAHANCA, 
EORTC, GORTEC, NCIC, RTOG consensus guidelines (Gregoire et al., 2003) and proposals 
for the delineation of the nodal clinical target volume in the node positive and the 
postoperative neck (Gregoire et al., 2006) (Fig. 1 a-b).  
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              a                            b 
Fig. 1. a-b. Sagital view of contoured clinical target volumes for elective neck nodal 
irradiation. a. Clinical target volume encompassing levels II, III, IV, and IV in patient with 
hypopharyngeal cancer arising from pyriform sinus apex with clinically negative neck. b. 
Clinical target volume encompassing levels I, II, III, IV, V, IV, retropharyngeal nodes and 
retrostyloid space in patient with hypopharyngeal cancer with esophageal extension and 
positive neck nodes in level II determined in the surgical specimen following neck 
dissection. 
6.5.3 Intensity modulated radiotherapy (IMRT)  
Clinical data evaluating the efficacy of IMRT for cancers of the hypopharynx are scarce, and 
the suggestions for satisfactory disease control come from small single-institution series 
with relatively short follow-up (Daly et al., 2011; Studer et al., 2006; Studer et al., 2010). 
Although prospective studies evaluating the efficacy and toxicity profile of IMRT to the 
hypopharynx are needed, IMRT techniques can be used to cover equivalent volumes of 
concern for hypopharyngeal cancers that involve the posterior pharyngeal wall, and for 
those primary tumours or metastatic lymphadenopathy that extending posterolaterally 
would overlie the spinal cord. The GTV is defined as all known gross disease determined 
from CT, MRI, clinical information, and endoscopic findings including abnormal lymph 
nodes identified on CT. The CTV1 is defined as the GTV with a 0.5-2 cm margin on primary 
and or nodal GTV (depending on the presence or absence of anatomic boundaries to 
microscopic spread). The CTV2 refers on the elective neck irradiation and includes the 
uninvolved neck lymph nodes. Final treatment target volumes include a PTV (GTV plus a 
margin of 0.3 to 0.5 cm margin), a PTV1 (CTV1 plus a margin of 0.3 to 0.5 cm margin), and a 
PTV2 (CTV2 plus a margin of 0.3 to 0.5 cm margin). Details about levels proposed for 
elective irradiation in dependence of the subsite of the primary tumour as well as with the 
nodal status are given in section 6.1.3.  
6.5.4 Dose prescriptions  
For small lesions (T1N0-1 and small T2N0), conventionally fractionated radiotherapy should 
be realised with a fraction size of 2 Gy to a total dose of 66 to 70 Gy.  
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For locally-regionally advanced lesions treated with concurrent chemoradiotherapy, 
conventional fractionation should be used with a total dose of 70 Gy in 7 weeks with a daily 
fraction of 2 Gy. 
For locally-regionally advanced lesions treated with definitive radiotherapy using altered 
fractionation regimens following options can be offered: hyperfractionated radiotherapy 
with 79.2 Gy in 66 fractions over 6.5 weeks using 1.2 Gy per fraction twice a day, or 
accelerated fractionation with concomitant boost delivering a total dose of 72 Gy in 6 weeks, 
(1.8 Gy per fraction a day for the large field and 1.5 Gy boost as second daily fraction during 
the last 12 treatment days). 
For lesions treated with postoperative radiotherapy or postoperative concurrent 
chemoradiotherapy, conventional fractionation with a total dose of 60 to 66 Gy at 2Gy per 
fraction to the postoperative bed and high-risk areas should be used. 
Elective neck irradiation to uninvolved nodal regions should be realised with a total dose of 
50 Gy using 2 Gy per fraction. 
If simultaneous integrated boost IMRT technique in 33 fractions is used, the recommended 
dose to the planning target volume PTV (i.e., GTV with a margin) is ~ 70 Gy at 2.12 Gy per 
fraction. The PTV1 will receive 59.4 Gy at 1.8 Gy per fraction, and PTV2 will receive 54 Gy at 
1.64 Gy per fraction. 
If simultaneous integrated boost IMRT technique in 35 fractions is used, the PTV (i.e., GTV 
with a margin) will receive 70 Gy at 2 Gy per fraction, the PTV1 will receive 63 Gy at 1.8 Gy 
per fraction, and PTV2 will receive 56 Gy at 1.6 Gy per fraction. 
If sequential IMRT technique is used, two to three different separate dose plans are used 
with initial lower dose phase (weeks 1-5) followed by high-dose boost volume phase (weeks 
6 and 7). 
If IMRT with concomitant boost schedule is used, the dose to subclinical targets is delivered 
once daily for 6 weeks, and a separate boost plan as second daily treatment is used for the 
last 12 treatment days. 
6.5.5 Dose limitations  
The maximum dose delivered to the spinal cord should range between 45 and 50 Gy. The 
maximum dose given to the brain stem is limited at 54 Gy. Mandible maximum dose is 
equal or less than 70 Gy. The mean dose to each parotid gland should be less than 26 Gy, 
and if possible, the dose to 50% of the volume of each parotid gland should be kept equal to 
or less than 20 Gy. The brachial plexus dose should be less than 60 Gy, and the dose to the 
tracheotomies is limited to 50 Gy. It should be also recognised that dose of 70 Gy carries 5% 
risk for laryngeal cartilage necrosis. 
7. Treatment of recurrent and metastatic hypopharyngeal cancer 
Surgery is the optimal therapy for patients with local and/or regional recurrence who were 
previously treated with radiotherapy alone or in combination with chemotherapy. The 
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reported successful salvage rate for local recurrence in hypopharyngeal cancer in the 
retrospective study of Taki et al. (Taki et al., 2010) was 17%. In the randomised controlled 
trial conducted at the Princess Margaret Hospital in Toronto, the overall survival rate at 3 
years after surgery salvage for patients with recurrent laryngopharyngeal cancer treated 
with primary radiotherapy was 22% (Davidson et al., 1997). Unfortunately, the vast majority 
of recurrent hypopharyngeal tumours appear to be unsuitable for surgical intervention 
because of their unresectibility mostly due to the presence of direct extension into the neck 
including encasement of the carotid artery. Additionally, there is also a proportion of 
recurrences that are technically resectable but could not be resected because of patient 
comorbidities or patient refusal.  
Radiotherapy with or without chemotherapy is the treatment of choice for patients initially 
treated with surgery alone. Reirradiation as an approach appearing to be a treatment with 
the most potential for cure in selected patients who previously underwent radiotherapy or 
chemoradiotherapy remains to be investigational. The reported local control rates following 
reirradiation for patients with recurrent head and neck cancer range between 13% and 42%, 
and 5-year survival rates range from 13% in unselected to 93% in highly selected series 
(Goldstein et al., 2008). However, the efficacy of reirradiation for hypopharyngeal cancer is 
difficult to be evaluated because most of the data are coming from series of highly 
heterogeneous patients.  
The addition of concurrent chemotherapy to reirradiation in the management of recurrences 
of head and neck cancer was a reasonable effort made to improve the results of treatment by 
improving the efficacy of radiotherapy through the radiosensitising effects of chemotherapy. 
Rates of overall survival at two years in multi-institutional trials of concurrent reirradiation 
and chemotherapy conducted by RTOG ranged between 17% and 25% (Horwitz et al., 2005; 
Spencer et al., 2001). Reirradiation alone and especially when combined with concurrent 
chemotherapy is associated with potentially severe and life-threatening treatment-related 
toxicities that occur in 9% to 32% of patients (Creak et al., 2005). Therefore, physicians, 
making a decision for the management of recurrent unresectable hypopharyngeal cancer, 
must be aware of the insufficient data confirming reirradiation as advocated standard of 
care and must balance the potential risk of severe complications and quality-of-life issues 
associated with reirradiation with only a small possibility for long-term survival.  
For patients with recurrent, hypopharyngeal cancer who are not candidates for salvage 
surgery or radiation treatment as well as for patients presenting with metastatic disease and 
therefore not eligible for multimodality potentially curative treatment, chemotherapy, being 
the historical palliative option, often represents the treatment of last resort. Generally aimed 
at prolonging survival, and also at improving the quality of life by controlling existing 
symptoms, and preventing of new cancer-related symptoms, chemotherapy, despite the use 
of more aggressive combinations and the achievement of higher response rates, has not been 
convincingly demonstrated to improve survival (Colevas, 2006). Further, despite the 
palliative intent of chemotherapy in this patients category, there is infrequent assessment of 
the correlation between tumour shrinkage and benefit such as symptom reduction, and 
there are also no generated data to support a positive impact of chemotherapy on patients’ 
quality of life. Clinical studies focused on the evaluation of the role of chemotherapy in  
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patients with incurable locoregionally recurrent or metastatic head and neck cancer are not 
site specific. The best studied single agents are methotrexate, cisplatin, 5-fluorouracil and 
the taxanes (paclitaxel and docetaxel). In general, the response rate of single-agent and 
combination chemotherapy ranges between 10% and 40% (Colevas, 2006; Vokes & Choong, 
2008). Various combinations of cytotoxic agents were compared in randomised clinical 
trials. The review analysis of these trials confirming the demonstrated statistically 
significant response superiority of combination versus monotherapy approaches has also 
shown that cisplatin and 5-fluorouracil was the only combination with superior response 
rate over single-agent chemotherapy without associated trend to a lower median survival 
(Browman & Cronin, 1994). Treatment results achieved in randomised studies exploring the 
role of different chemotherapy regimens in the treatment of recurrent or metastatic head 
and neck cancer are summarised in Table 4. The utility of paclitaxel plus cisplatin in patients 
with recurrent or metastatic head and neck cancer was defined in two randomised trials 
conducted by the ECOG (Forastiere et al., 2001b; Gibson et al., 2005) (Table 4). In the 
randomised study of Vermorken et al. (Vermorken et al., 2008) conducted to investigate the 
efficacy of cetuximab plus platinum-based chemotherapy as first-line treatment in patients 
with recurrent or metastatic head and neck cancer, the combination of platinum agent 
(either cisplatin or carboplatin), 5-fluorouracil, and cetuximab has been shown to 
significantly improve the median overall survival and progression-free survival as 
compared with chemotherapy alone consisting of platinum agent and 5-fluorouracil (Table 
4). Although there are many options for palliative chemotherapy in patients with recurrent 
or metastatic head and neck cancer, treatment commencement should not ultimately follow 
the documentation of recurrent disease or presence of distant metastases. However, 
patients’ selection focused on relation between possible benefits of palliation and the risks of 
treatment induced toxicity should represent more important procedure than the selection of 
particular cytotoxic agents. Regimens in wide clinical use are: methotrexate given at 40 to 60 
mg/m2 intravenously weekly; paclitaxel 80-100 mg/m2 given as 1-hour weekly infusion; 
docetaxel given intravenously at 75-100 mg/m2 over 1 hour every 21 days; cisplatin-5-
fluorouracil combination with cisplatin 100 mg/m2 given intravenously on day 1 and 5-
fluorouracil 1,000 mg/m2 every day given as continuous infusion over days 1 to 4, repeated 
every 21 to 28 days; cisplatin-paclitaxel combination with cisplatin 75 mg/m2 given 
intravenously and paclitaxel 175 mg/m2 given intravenously over 3 hours, both on day 1, 
repeated every 21 days; cisplatin-docetaxel combination with cisplatin 75 mg/m2 given 
intravenously and docetaxel 75 mg/m2 given intravenously over 1 hour, both on day 1 and 
repeated every 21 days; carboplatin-paclitaxel combination with carboplatin given at Area 
Under the Curve (AUC) 6 and paclitaxel 200 mg/m2 given intravenously over 3 hours, both 
on day 1, every 21 days, or carboplatin given at AUC 2 and paclitaxel 80 mg/m2 given 
intravenously over 1 hour, both on day 1 administered on a weekly basis. 
8. Complications of treatment 
Poor general health, chronic malnutrition, alcoholism, and advanced age of the patient, or 
the use of preoperative radiotherapy, represent factors influencing the increased risk for 
surgical complications. Hemorrhage and damage to cranial nerves are most frequently 
observed intraoperative complications. The most common complication after 
laryngopharyngectomy is pharyngocutaneous fistula as a result from a leakage at the site of 
the pharyngeal closure that might be a consequence of tight closure or presence of tumour at 
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Authors Therapy regimens Response rate % 
(CR %) 
Median survival 
(months) 
    
Taylor et al. 
(Taylor et al., 
1984) 
MTX 1,500 mg/m2 given as continuous 
infusion over 24 hours with leucovorin vs. 40 
mg/m2 given i.m. 
32 vs. 22; p=0.52 4.2 for both 
treatments 
    
Vogl et al. 
(Vogl et al., 
1985) 
MTX 40 mg/m2 i.v. weekly, with escalation to 
60 mg/m2 on day 8 and subsequently in the 
absence of toxicity vs. MTX 40 mg/m2 i.m. on 
days 1 and 15, bleomycin 10 U i.m. on day 1, 8 
and 15, and cisplatin 50 mg/m2 i.v. on day 4, 
repeated every 21 days 
35 vs. 48; p=0.04 
(8 vs. 16; p=0.04) 
5.6 for both 
treatments 
    
Williams et al. 
(Williams et 
al., 1986) 
MTX 45 mg/m2 given as weekly i.v. bolus 
with escalation to 60 mg/m2 in the absence of 
toxicity v.s. four-week courses of cisplatin 60 
mg/m2 on day 1 plus vinblastine 0.1 mg/kg 
on days 1 and 15 i.v. plus bleomycin 15 U i.v. 
weekly 
16 vs. 24; n.s. 7.8 vs. 7.2; n.s. 
    
Eisenberger et 
al. 
(Eisenberger et 
al., 1989) 
MTX 40 mg/m2 given i.v. weekly vs. 
carboplatin 400 mg/m2 given i.v. monthly in 
combination with MTX given at the same 
dose/schedule 
25 vs. 25; n.s. 2 vs. 3; n.s. 
    
Forastiere et 
al. 
(Forastiere et 
al., 1992) 
MTX 40 mg/m2 given i.v. weekly (MTX) vs. 
cisplatin 100 mg/m2 given i.v. on day 1 and 5-
FU 1,000 mg/m2 per day for a 96-hour 
continuous infusion, repeated every 21 days 
(CP + 5FU) vs. carboplatin 300 mg/m2 given 
i.v. on day 1 and 5-FU 1,000 mg/m2 per day 
for a 96-hour continuous infusion, repeated 
every 28 days (CB + 5-FU) 
10 vs. 32 vs. 21; CP + 5-
FU superior to MTX 
with p<0.001 
5.6 vs. 6.6 vs. 5.0; 
n.s. 
    
Jacobs et al. 
(Jacobs et al., 
1992) 
Cisplatin 100 mg/m2 given i.v. on day 1 and 5-
FU 1,000 mg/m2 per day for a 96-hour 
continuous infusion, repeated every 21 days 
(CP + 5-FU) vs. cisplatin 100 mg/m2 given i.v. 
on day 1 and repeated every 21 days (CP) v.s 
5-FU 1,000 mg/m2 per day for a 96-hour 
continuous infusion, repeated every 21 days 
(5-FU) 
32 vs. 17 vs.  13; CP + 5-
FU superior to CP and 
to 5-FU with p=0.035 
5.7 for all treatments 
    
Clavel et al. 
(Clavel et al., 
1994) 
MTX 40 mg/m2 given i.v. on days 1 and 15, 
weekly, bleomycin 10 mg and vincristine 2 mg 
given on days 1, 8 and 15, CP 50 mg/m2 given on 
day 4, repeated every 21 days (CABO) vs. 
cisplatin 100 mg/m2 given i.v. on day 1 and 5-FU 
1,000 mg/m2 per day for a 96-hour continuous 
infusion, repeated every 21 days (CF) vs. cisplatin 
50 mg/m2 given on days 1 and 8, repeated every 
28 days (C) 
34 vs. 31 vs. 15; CABO 
and CF superior to C 
with p<0.001, p=0.003, 
respectively 
(9.5 vs. 1.7 vs. 2.5; CABO 
superior to CF with 
p=0.01 and superior to 
C with p=0.02) 
7.3 for all treatments 
www.intechopen.com
 Hypopharyngeal Cancer 
 
45 
Authors Therapy regimens Response rate % 
(CR %) 
Median survival 
(months) 
    
Schrijvers et al. 
(Schrijvers et 
al., 1998) 
Cisplatin 100 mg/m2 given i.v. on day 1 and 5-
FU 1,000 mg/m2 per day for a 96-hour 
continuous infusion, repeated every 21 days 
vs. same schedule with interferon alfa-2b 
given s.c. 3 x 106 U/day on days 1 to 5, 
repeated every 21 days 
47 vs. 48; p<0.70 
(10.7 vs. 6.8; p<0.50) 
6.3 vs. 6; p=0.49 
    
Forastiere et 
al. 
(Forastiere et 
al., 2001b) 
Paclitaxel 200 mg/m2 for a 24-hour 
continuous infusion plus cisplatin 75 mg/m2 + 
granulocyte colony-stimulating factor, 
repeated every 21 days vs. paclitaxel 135 
mg/m2 for a 24-hour continuous infusion plus 
cisplatin 75 mg/m2, repeated every 21 days 
35 vs. 36; n.s. 
(4 vs. 12; p=0.038) 
7.6 vs. 6.8; p=0.759 
    
Gibson et al. 
(Gibson et al., 
2005) 
Cisplatin 100 mg/m2 given i.v. on day 1 and 5-
FU 1,000 mg/m2 per day for a 96-hour 
continuous infusion, repeated every 21 days 
vs. cisplatin 75 mg/m2 given i.v. on day 1 and 
paclitaxel 175 mg/m2 given over 3 hours on 
day 1, repeated every 21 days 
27 vs. 26; n.s. 
(6.7 vs. 7.0; n.s.) 
8.7 vs. 8.1; n.s. 
    
Burtness et al. 
(Burtness et 
al., 2005) 
Cetuximab 200 mL/m2 given i.v. on day 1 
over 2 hours for cycle 1, and in subsequent 
cycles cetuximab 125 mL/m2 given i.v. weekly 
over 1-hour plus cisplatin 100 mg/m2 given 
i.v. on day 1 every 4 weeks vs. placebo plus 
cisplatin 100 mg/m2 given i.v. on day 1 every 
4 weeks 
26 vs. 10; p=0.03 8.0 vs. 9.2; 
p=0.21 
    
Vermorken et 
al. (Vermorken 
et al., 2008) 
Cisplatin 100 mg/m2 given i.v. on day 1 or 
carboplatin 5 mg per milliliter per minute at 
an AUC given on day 1 as a 1-hour infusion 
plus 5-FU 1,000 mg/m2 per day for a 96-hour 
continuous infusion, repeated every 21 days 
vs. the same chemotherapy regimen plus 
cetuximab 400 mg/m2 given initially as 
intravenous infusion over 2-hours, then 250 
mg/m2 given weekly as a 1-hour intravenous 
infusion 
20 vs. 36; p<0.001 7.4 vs. 10; 
p=0.04 
CR: complete response; MTX: methotrexate; i.m.: intramuscularly; i.v.: intravenously; U: units; 5-FU: 5-
fluorouracil; s.c.: subcutaneously; AUC: area under the curve  
Table 4. Randomised studies of chemotherapy in recurrent/metastatic head and neck cancer  
the margins of resection. Aspiration pneumonia after partial laryngectomy is postoperative 
complication occasionally requiring total laryngectomy. Pharyngeal stenosis is commonly 
manifested following a jejunal free flap reconstruction of a total laryngopharyngectomy. 
Late complications include pharyngoesophageal stenosis and stricture, chronic 
pharyngocutaneous fistula and functional deficits in swallowing. 
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Acute ccomplications of radiotherapy include development of mucositis, dermatitis, 
xerostomia, and dysgeusia. Acute mucositis as the most frequently observed radiation-
induced morbidity is related to the intensity of the treatment regimen with a greater 
incidence of grade 3-4 reactions associated with accelerated fractionation and concurrent 
chemoradiotherapy. The occurrence of arytenoid edema being well known consequence of 
radiotherapy lead to tracheotomy in less than 10% of patients. Late complications of 
radiotherapy include fibrosis of the soft tissues in the neck, fibrosis of the esophagus, which 
may develop into an esophageal stricture or tracheoesophageal fistula, and radiation-
induced hypothyroidism requiring thyroid-replacement therapy. Rarely seen, but 
potentially serious late complications are carotid rupture, pharyngocutaneous fistula, 
laryngeal chondronecrosis or soft tissue necrosis of the posterior pharyngeal wall, laryngeal 
strictures, brachial plexus injury, and the possibility of spinal cord injury. When keeping the 
dose to the spinal cord under 50 Gy, myelitis is rarely occurred complication (Emami et al., 
1991; Marcus & Million, 1990). However, L’Hermitte sign can occur 2 to 3 months after 
treatment and last several weeks to months. 
Chemotherapy complications include adverse effects in dependence of the specific cytotoxic 
agents used. Cisplatin-based regimens induce nausea and vomiting, and cumulative 
toxicities from cisplatin such as ototoxicity, peripheral neuropathy, nephrotoxicity, or 
myelosuppression. The use of 5-fluorouracil can cause myelosuppression in addition to 
mucositis, diarrhoea, and vascular irritation. Common adverse effects of taxanes are 
peripheral neuropathy, myelosuppression, alopecia, and potential hypersensitivity 
reactions. 
9. Follow-up  
Post treatment follow-up is required to evaluate treatment response, and is also intended to 
detect early recurrence, and identify second primary cancers. The majority of local 
recurrences occur within the first 2 years of treatment (Fu et al., 2000; Ho et al., 1993). 
Independent second malignancies in the upper aerodigestive tract have an annual incidence 
of approximately 3% (Cooper et al., 1989; Spector et al., 2001), and the risk for their 
development is not time limited.  
Patients should be followed up every 1-3 months over the first year after treatment, every 2-
4 months in the second year after treatment, every 4-6 months in the third through the fifth 
years after treatment, and every 6-12 months thereafter (National Comprehensive Cancer 
Network [NCCN], 2011).  
Each follow-up examination should include history, physical examination, and fiberoptic 
endoscopy, or indirect mirror exam. Diagnostic imaging of the neck should be performed 
for the assessment of response to treatment and must be also performed in any patient with 
new signs and symptoms suggesting recurrence development. If PET-CT scan is used for 
follow-up, the first scan should be performed at not less than 3 months after treatment to 
reduce false-positive scans that can result from active inflammation following treatment 
(Robson, 2002). Biopsy is mandatory if there is clinical suspicion of residual or recurrent 
disease. Annual chest is primarily recommended for detection of second primary tumours. 
In patients who received surgery or radiation to a substantial proportion of the thyroid 
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gland, monitoring of thyroid-stimulating hormone (TSH) levels is recommended every  
6 to 12 months. 
10. Conclusion 
Patients with early-stage hypopharyngeal cancers including T1N0-1 and small T2N0 lesions 
achieve satisfactory rates of local control when treated with either conservation surgery or 
radiotherapy as a single treatment modality. Patients with locally-regionally advanced 
resectable hypopharyngeal cancers could be treated with radical surgery followed by 
postoperative radiotherapy or postoperative concurrent chemoradiotherapy. In patients 
with advanced resectable hypopharyngeal cancers requiring laryngopharyngectomy for the 
surgical approach, concurrent chemoradiotherapy or altered fractionation radiotherapy are 
treatment modalities allowing anatomic and functional organ preservation while 
demonstrating equivalent results in terms of survival with those obtained with immediate 
surgery. For patients presenting with unresectable hypopharyngeal cancer without evidence 
of distant metastases, radiotherapy and concurrent cisplatin-based chemotherapy should be 
considered standard treatment approach. The adoption of IMRT, considering its more 
conformal dose distribution with steep gradients between planning target volumes and 
critical structures, should be advocated in the routine clinical practice as radiotherapy 
technique in the treatment of hypopharyngeal cancer.  
However, patients with early stage disease are relatively rare, and for those with advanced 
disease being most frequently present, the results in the achievement of long-term control 
and survival with the advancement made using aggressive therapeutic approaches remain 
quite unsatisfactory. Sequential therapy (induction chemotherapy followed by concurrent 
chemoradiotherapy), intensified radiotherapy regimens in combination with chemotherapy, 
and the incorporation of molecular targeted therapies in combination with traditional 
chemotherapy and radiotherapy are strategies currently investigated in an effort to improve 
outcomes in patients with advanced hypopharyngeal cancer. 
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